Patent Grant
12129300
The instant application contains a Sequence Listing which has been submitted electronically in XML format and is hereby incorporated by reference in its entirety. Said XML copy, created on Oct. 13, 2023, is named DFY-048D2.xml and is 114,286 bytes in size.
The invention provides proteins with antibody heavy chain and light chain variable domains that can be paired to form an antigen-binding site targeting the Natural Killer group 2D (NKG2D) receptor on natural killer cells, pharmaceutical compositions comprising such proteins, and therapeutic methods using such proteins and pharmaceutical compositions, including for the treatment of cancer.
Cancer continues to be a significant health problem despite the substantial research efforts and scientific advances reported in the literature for treating this disease. Some of the most frequently diagnosed cancers include prostate cancer, breast cancer, and lung cancer. Prostate cancer is the most common form of cancer in men. Breast cancer remains a leading cause of death in women. Current treatment options for these cancers are not effective for all patients and/or can have substantial adverse side effects. Other types of cancer also remain challenging to treat using existing therapeutic options.
Cancer immunotherapies are desirable because they are highly specific and can facilitate destruction of cancer cells using the patient's own immune system. Fusion proteins such as bi-specific T-cell engagers are cancer immunotherapies described in the literature that bind to tumor cells and T-cells to facilitate destruction of tumor cells. Antibodies that bind to certain tumor-associated antigens and to certain immune cells have been described in the literature. See, for example WO 2016/134371 and WO 2015/095412.
Natural killer (NK) cells are a component of the innate immune system and make up approximately 15% of circulating lymphocytes. NK cells infiltrate virtually all tissues and were originally characterized by their ability to kill tumor cells effectively without the need for priming, which distinguishes them from T cells. Activated NK cells kill target cells by means similar to cytotoxic T cells—i.e., via cytolytic granules that contain perforin and granzymes as well as via death receptor pathways. Activated NK cells also secrete inflammatory cytokines such as IFN-gamma and chemokines that promote the recruitment of other leukocytes to the target tissue.
NK cells respond to signals through a variety of activating and inhibitory receptors on their surface. For example, when NK cells encounter healthy self-cells, their activity is inhibited through activation of the killer-cell immunoglobulin-like receptors (KIRs). Alternatively, when NK cells encounter cancer cells, they are activated via their activating receptors (e.g., NKG2D, NCRs, DNAM1). NK cells are also activated by the constant region of some immunoglobulins through CD16 receptors on their surface. The overall sensitivity of NK cells to activation depends on the sum of stimulatory and inhibitory signals. NKG2D is a type-II transmembrane protein that is expressed by essentially all natural killer cells where NKG2D serves as an activating receptor. The ability to modulate NK cell function via NKG2D is useful in various therapeutic contexts including malignancy.
Antibodies to NKG2D have been identified that provide important advantages in the design of therapeutic agents. For example, some of these antibodies do not merely bind human NKG2D receptor, but have one or more further advantages such as the ability to agonize the receptor; the ability to compete with a natural ligand for binding to the receptor; and/or the ability to cross-react with NKG2D from other species such as cynomolgus monkey. These advantages can be achieved across a range of affinities for NKG2D.
Accordingly, one aspect of the invention relates to an antibody heavy chain variable domain at least 90% identical to the amino acid sequence QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGS TSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGAPNYGDTTHDYYYMD VWGKGTTVTVSS (SEQ ID NO:1, ADI-29379). In some embodiments, the antibody heavy chain variable domain is at least 95% identical to SEQ ID NO:1. In some embodiments, the heavy chain variable domain includes amino acid sequences YTFTSYYMH (SEQ ID NO:11) as the first complementarity-determining region 1 (“CDR1”), IINPSGGSTSYAQKFQG (SEQ ID NO:12) as the second CDR (“CDR2”), and ARGAPNYGDTTHDYYYMDV (SEQ ID NO:13) as the third CDR (“CDR3”) of SEQ ID NO:1. In some embodiments, the heavy chain variable domain includes amino acid sequences SYYMH (SEQ ID NO:45) as CDR1, IINPSGGSTSYAQKFQG (SEQ ID NO:12) as CDR2, and GAPNYGDTTHDYYYMDV (SEQ ID NO:68) as CDR3 of SEQ ID NO:1.
Another aspect of the invention relates to an antibody heavy chain variable domain at least 90% identical to the amino acid sequence QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSG GTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDTGEYYDTDDHGMDV WGQGTTVTVSS (SEQ ID NO: 3, ADI-29463). In some embodiments, the antibody heavy chain variable domain is at least 95% identical to SEQ ID NO:3. In some embodiments, the heavy chain variable domain includes amino acid sequences YTFTGYYMH (SEQ ID NO: 17) as the first complementarity-determining region (“CDR1”), WINPNSGGTNYAQKFQG (SEQ ID NO:18) as the second CDR (“CDR2”), and ARDTGEYYDTDDHGMDV (SEQ ID NO:19) as the third CDR (“CDR3”) of SEQ ID NO:3. In some embodiments, the heavy chain variable domain includes amino acid sequences GYYMH (SEQ ID NO: 92) as CDR1, WINPNSGGTNYAQKFQG (SEQ ID NO:18) as CDR2, and DTGEYYDTDDHGMDV (SEQ ID NO:69) as CDR3 of SEQ ID NO:3.
Another aspect of the invention relates to an antibody heavy chain variable domain at least 90% identical to the amino acid sequence EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTY YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDGGYYDSGAGDYWGQGTL VTVSS (SEQ ID NO:5, ADI-27744). In some embodiments, the antibody heavy chain variable domain is at least 95% identical to SEQ ID NO:5. In some embodiments, the heavy chain variable domain includes amino acid sequences FTFSSYAMS (SEQ ID NO:23) as the first complementarity-determining region (“CDR1”), AISGSGGSTYYADSVKG (SEQ ID NO:24) as the second CDR (“CDR2”), and AKDGGYYDSGAGDY (SEQ ID NO:25) as the third CDR (“CDR3”) of SEQ ID NO:5. In some embodiments, the heavy chain variable domain includes amino acid sequences SYAMS (SEQ ID NO:47) as CDR1, AISGSGGSTYYADSVKG (SEQ ID NO:24) as CDR2, and DGGYYDSGAGDY (SEQ ID NO:70) as CDR3 of SEQ ID NO:5.
Another aspect of the invention relates to an antibody heavy chain variable domain at least 90% identical to the amino acid sequence EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIY YADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGAPMGAAAGWFDPWGQG TLVTVSS (SEQ ID NO:7, ADI-27749). In some embodiments, the antibody heavy chain variable domain is at least 95% identical to SEQ ID NO:7. In some embodiments, the heavy chain variable domain includes amino acid sequences FTFSSYSMN (SEQ ID NO:29) as the first complementarity-determining region (“CDR1”), SISSSSSYIYYADSVKG (SEQ ID NO: 30) as the second CDR (“CDR2”), and ARGAPMGAAAGWFDP (SEQ ID NO:31) as the third CDR (“CDR3”) of SEQ ID NO:7. In some embodiments, the heavy chain variable domain includes amino acid sequences SYSMN (SEQ ID NO:48) as CDR1, SISSSSSYIYYADSVKG (SEQ ID NO: 30) as CDR2, and GAPMGAAAGWFDP (SEQ ID NO:71) as CDR3 of SEQ ID NO:7.
Another aspect of the invention relates to an antibody heavy chain variable domain at least 90% identical to the amino acid sequence EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIY YADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGAPIGAAAGWFDPWGQGT LVTVSS (SEQ ID NO:85, A49MI). In some embodiments, the antibody heavy chain variable domain is at least 95% identical to SEQ ID NO:85. In some embodiments, the heavy chain variable domain includes amino acid sequences FTFSSYSMN (SEQ ID NO:29) as CDR1, SISSSSSYIYYADSVKG (SEQ ID NO: 30) as CDR2, and ARGAPIGAAAGWFDP (SEQ ID NO:77) as CDR3 of SEQ ID NO:85. In some embodiments, the heavy chain variable domain includes amino acid sequences SYSMN (SEQ ID NO:48) as CDR1, SISSSSSYIYYADSVKG (SEQ ID NO: 30) as CDR2, and GAPIGAAAGWFDP (SEQ ID NO:78) as CDR3 of SEQ ID NO:85.
Another aspect of the invention relates to an antibody heavy chain variable domain at least 90% identical to the amino acid sequence QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGS TSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCAREGAGFAYGMDYYYMDV WGKGTTVTVSS (SEQ ID NO:9, ADI-29378). In some embodiments, the antibody heavy chain variable domain is at least 95% identical to SEQ ID NO:9. In some embodiments, the heavy chain variable domain includes amino acid sequences YTFTSYYMH (SEQ ID NO:35) as the first complementarity-determining region (“CDR1”), IINPSGGSTSYAQKFQG (SEQ ID NO: 36) as the second CDR (“CDR2”), and AREGAGFAYGMDYYYMDV (SEQ ID NO:37) as the third CDR (“CDR3”) of SEQ ID NO:9. In some embodiments, the heavy chain variable domain includes amino acid sequences SYYMH (SEQ ID NO:45) as CDR1, IINPSGGSTSYAQKFQG (SEQ ID NO: 36) as CDR2, and EGAGFAYGMDYYYMDV (SEQ ID NO:72) as CDR3 of SEQ ID NO:9.
An antibody heavy chain variable domain of the invention can optionally be coupled to an amino acid sequence at least 90% identical to an antibody constant region, such as an IgG constant region including hinge, CH2 and CH3 domains with or without CH1 domain. In some embodiments, the amino acid sequence of the constant region is at least 90% identical to a human antibody constant region, such as an human IgG1 constant region, an IgG2 constant region, IgG3 constant region, or IgG4 constant region. In some other embodiments, the amino acid sequence of the constant region is at least 90% identical to an antibody constant region from another mammal, such as rabbit, dog, cat, mouse, or horse. One or more mutations can be included into the constant region as compared to human IgG1 constant region, for example at Q347, Y349, L351, S354, E356, E357, K360, Q362, S364, T366, L368, K370, N390, K392, T394, D399, S400, D401, F405, Y407, K409, T411 and/or K439. Exemplary substitutions include, for example, Q347E, Q347R, Y349S, Y349K, Y349T, Y349D, Y349E, Y349C, T350V, L351K, L351D, L351Y, S354C, E356K, E357Q, E357L, E357W, K360E, K360W, Q362E, S364K, S364E, S364H, S364D, T366V, T366I, T366L, T366M, T366K, T366W, T366S, L368E, L368A, L368D, K370S, N390D, N390E, K392L, K392M, K392V, K392F, K392D, K392E, T394F, T394W, D399R, D399K, D399V, S400K, S400R, D401K, F405A, F405T, Y407A, Y407I, Y407V, K409F, K409W, K409D, T411D, T411E, K439D, and K439E.
In certain embodiments, mutations that can be included into the CH1 of a human IgG1 constant region may be at amino acid V125, F126, P127, T135, T139, A140, F170, P171, and/or V173. In certain embodiments, mutations that can be included into the Cκ of a human IgG1 constant region may be at amino acid E123, F116, S176, V163, S174, and/or T164.
In some embodiments, one of the heavy chain variable domains described herein is combined with a light chain variable domain to form an antigen-binding site capable of binding NKG2D. For example, an antibody heavy chain variable domain at least 90% identical to the amino acid sequence of SEQ ID NO:1 can be paired with an antibody light chain variable domain at least 90% identical to the amino acid sequence EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPA RFSGSGSGTEFTLTISSLQSEDFAVYYCQQYDDWPFTFGGGTKVEIK (SEQ ID NO:2, ADI-29379). In some embodiments, the antibody light chain variable domain is at least 95% identical to SEQ ID NO:2. In some embodiments, the light chain variable domain includes amino acid sequences RASQSVSSNLA (SEQ ID NO:14) as the first complementarity-determining region (“CDR”), GASTRAT (SEQ ID NO:15) as the second CDR, and QQYDDWPFT (SEQ ID NO:16) as the third CDR.
For example, an antibody heavy chain variable domain at least 90% identical to the amino acid sequence of SEQ ID NO:3 can be paired with an antibody light chain variable domain at least 90% identical to the amino acid sequence EIVLTQSPGTLSLSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPAR FSGSGSGTEFTLTISSLQSEDFAVYYCQQDDYWPPTFGGGTKVEIK (SEQ ID NO:4, ADI-29463). In some embodiments, the antibody light chain variable domain is at least 95% identical to SEQ ID NO:4. In some embodiments, the light chain variable domain includes amino acid sequences RASQSVSSNLA (SEQ ID NO:20) as the first complementarity-determining region (“CDR”), GASTRAT (SEQ ID NO:21) as the second CDR, and QQDDYWPPT (SEQ ID NO:22) as the third CDR.
For example, an antibody heavy chain variable domain at least 90% identical to the amino acid sequence of SEQ ID NO:5 can be paired with an antibody light chain variable domain at least 90% identical to the amino acid sequence DIQMTQSPSSVSASVGDRVTITCRASQGIDSWLAWYQQKPGKAPKLLIYAASSLQSGVPS RFSGSGSGTDFTLTISSLQPEDFATYYCQQGVSYPRTFGGGTKVEIK (SEQ ID NO:6, ADI-27744). In some embodiments, the antibody light chain variable domain is at least 95% identical to SEQ ID NO:6. In some embodiments, the light chain variable domain includes amino acid sequences RASQGIDSWLA (SEQ ID NO:26) as the first complementarity-determining region (“CDR”), AASSLQS (SEQ ID NO:27) as the second CDR, and QQGVSYPRT (SEQ ID NO:28) as the third CDR.
For example, an antibody heavy chain variable domain at least 90% identical to the amino acid sequence of SEQ ID NO:7 or 85 can be paired with an antibody light chain variable domain at least 90% identical to the amino acid sequence DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASSLQSGVPS RFSGSGSGTDFTLTISSLQPEDFATYYCQQGVSFPRTFGGGTKVEIK (SEQ ID NO:8, ADI-27749). In some embodiments, the antibody light chain variable domain is at least 95% identical to SEQ ID NO:8. In some embodiments, the light chain variable domain includes amino acid sequences RASQGISSWLA (SEQ ID NO:32) as the first complementarity-determining region (“CDR”), AASSLQS (SEQ ID NO:33) as the second CDR, and QQGVSFPRT (SEQ ID NO:34) as the third CDR.
For example, an antibody heavy chain variable domain at least 90% identical to the amino acid sequence of SEQ ID NO:9 can be paired with an antibody light chain variable domain at least 90% identical to the amino acid sequence EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPA RFSGSGSGTDFTLTISSLEPEDFAVYYCQQSDNWPFTFGGGTKVEIK (SEQ ID NO:10, ADI-29378). In some embodiments, the antibody light chain variable domain is at least 95% identical to SEQ ID NO:10. In some embodiments, the light chain variable domain includes amino acid sequences RASQSVSSYLA (SEQ ID NO:38) as the first complementarity-determining region (“CDR”), DASNRAT (SEQ ID NO:39) as the second CDR, and QQSDNWPFT (SEQ ID NO:40) as the third CDR.
When a heavy chain variable domain is combined with a light chain variable domain to form an antigen-binding site capable of binding NKG2D, the antigen-binding site can be included into a variety of structures, for example, a typical antibody structure with two identical heavy chains and two identical light chains, forming a pair of antigen-binding sites capable of binding NKG2D; a bi-specific, tri-specific, tetra-specific or other multi-specific antibody; or a smaller structure such as an scFv (in which the heavy chain variable domain is linked to the light chain variable domain).
In some embodiments, any NKG2D antigen-binding site disclosed in the instant invention is included into a protein that also includes a separate antigen-binding site that binds a tumor-associated antigen, which may permit the protein to simultaneously interact with an NK cell and a tumor cell. The tumor-associated antigen, for example, can be CD33, HER2, EpCAM, CD2, CD3, CD8, CD10, CD19, CD20, CD21, CD22, CD23, CD24, CD25, CD30, CD37, CD38, CD40, CD45RO, CD48, CD52, CD55, CD59, CD70, CD74, CD80, CD86, CD138, CD147, HLA-DR, CSAp, CA-125, TAG-72, EFGR/ERBB1, IGF1R, HER2, HER3, HER4, IGF-1R, c-Met, PDGFR, MUC1, MUC2, MUC3, MUC4, TNFR1, TNFR2, NGFR, TRAILR1, TRAILR2, Fas (CD95), DR3, DR4, DR5, DR6, VEGF, PIGF, tenascin, ED-B fibronectin, PSA, and IL-6, MAGE-A3, B7.1, B7.2, CTLA4 or PD1.
In some embodiments, any NKG2D antigen-binding site disclosed in the instant invention is included into a protein that also contain a tumor-associated antigen site and CD16 binding site. The CD16 binding site can be an additional antigen-binding site or an antibody constant region or a portion thereof, such as an IgG1 constant region (which may optionally include one or more mutations affecting, for example, effector activity or CD16 binding affinity).
Another aspect of the invention provides a method of enhancing tumor cell death and treating cancer in a patient. The method comprises administering to a patient in need thereof a therapeutically effective amount of a protein described herein to treat the cancer.
The invention provides antibody heavy chain variable domains that can be paired with antibody light chain variable domains to form an antigen-binding site targeting the NKG2D receptor on natural killer cells, proteins that include the NKG2D antigen-binding sites, pharmaceutical compositions comprising such proteins, and therapeutic methods using such proteins and pharmaceutical compositions for the treatment of cancer. Various aspects of the invention are set forth below in sections; however, aspects of the invention described in one particular section are not to be limited to any particular section.
To facilitate an understanding of the present invention, a number of terms and phrases are defined below.
The terms “a” and “an” as used herein mean “one or more” and include the plural unless the context is inappropriate.
As used herein, the terms “subject” and “patient” refer to an organism to be treated by the methods and compositions described herein. Such organisms preferably include, but are not limited to, mammals (e.g., murines, simians, equines, bovines, porcines, canines, felines, and the like), and more preferably include humans.
As used herein, the term “antigen-binding site” refers to the part of the immunoglobulin molecule that participates in antigen binding. In human antibodies, the antigen-binding site is formed by amino acid residues of the N-terminal variable (“V”) regions of the heavy (“H”) and light (“L”) chains. Three highly divergent stretches within the V regions of the heavy and light chains are referred to as “hypervariable regions” which are interposed between more conserved flanking stretches known as “framework regions,” or “FRs.” Thus the term “FR” refers to amino acid sequences which are naturally found between and adjacent to hypervariable regions in immunoglobulins. In a human antibody molecule, the three hypervariable regions of a light chain and the three hypervariable regions of a heavy chain are disposed relative to each other in three dimensional space to form an antigen-binding surface. The antigen-binding surface is complementary to the three-dimensional surface of a bound antigen, and the three hypervariable regions of each of the heavy and light chains are referred to as “complementarity-determining regions,” or “CDRs.” In certain animals, such as camels and cartilaginous fish, the antigen-binding site is formed by a single antibody chain providing a “single domain antibody.” Antigen-binding sites can exist in an intact antibody, in an antigen-binding fragment of an antibody that retains the antigen-binding surface, or in a recombinant polypeptide such as an scFv, using a peptide linker to connect the heavy chain variable domain to the light chain variable domain in a single polypeptide.
As used herein, the term “effective amount” refers to the amount of a compound (e.g., a compound of the present invention) sufficient to effect beneficial or desired results. An effective amount can be administered in one or more administrations, applications or dosages and is not intended to be limited to a particular formulation or administration route. As used herein, the term “treating” includes any effect, e.g., lessening, reducing, modulating, ameliorating or eliminating, that results in the improvement of the condition, disease, disorder, and the like, or ameliorating a symptom thereof.
As used herein, the term “pharmaceutical composition” refers to the combination of an active agent with a carrier, inert or active, making the composition especially suitable for diagnostic or therapeutic use in vivo or ex vivo.
As used herein, the term “pharmaceutically acceptable carrier” refers to any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water, emulsions (e.g., such as an oil/water or water/oil emulsions), and various types of wetting agents. The compositions also can include stabilizers and preservatives. For examples of carriers, stabilizers and adjuvants, see e.g., Martin, Remington's Pharmaceutical Sciences, 15th Ed., Mack Publ. Co., Easton, PA [1975].
Throughout the description, where compositions are described as having, including, or comprising specific components, or where processes and methods are described as having, including, or comprising specific steps, it is contemplated that, additionally, there are compositions of the present invention that consist essentially of, or consist of, the recited components, and that there are processes and methods according to the present invention that consist essentially of, or consist of, the recited processing steps.
As a general matter, compositions specifying a percentage are by weight unless otherwise specified. Further, if a variable is not accompanied by a definition, then the previous definition of the variable controls.
NKG2D Antigen-Binding Site
The invention provides antigen-binding sites that bind NKG2D, and antigen heavy chain variable domains that can be used to create such antigen-binding sites.
Antibody heavy chain variable domains and the light chain variable domains which they pair to form antigen-binding sites capable of binding and agonizing the NKG2D receptor have now been identified and are provided in Table 1, below. Unless otherwise indicated, the CDR sequences provided in Table 1 are determined under Kabat.
One advantage of one or more of the antibody heavy chain variable domain amino acid sequences described above is that they can bind to NKG2D from humans and cynomolgus monkeys to agonize the receptor, and compete with natural ligands for binding to the receptor. Additional antigen-binding sites that bind NKG2D and share one or more of these properties are also particularly useful and can be identified by binding competition assays known in the art. For example, the additional antigen-binding sites can be identified by competition with ADI-29379, ADI-29463, ADI-27744, ADI-27749, or ADI-29378 for binding to both human and optionally cynomolgus monkey NKG2D.
Another advantage of the NKG2D-binding sites which comprise the antibody heavy chain variable domains and light chain variable domains sequences described above is that they can bind to NKG2D with high affinity. In some embodiments, NKG2D-binding sites bind to NKG2D with a KD of 0.1 to 1000 nM. In some embodiments, NKG2D-binding sites bind to NKG2D with a KD of 1 to 500 nM. In some embodiments, NKG2D-binding sites bind to NKG2D with a KD of 5 to 100 nM. In some embodiments, NKG2D-binding sites bind to NKG2D with a KD of 10 to 62 nM.
In certain embodiments, the present invention provides an antigen-binding site that includes an antibody heavy chain variable domain that includes an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:1, and an antibody light chain variable domain that includes an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:2. In certain embodiments, an antigen-binding site that includes an antibody heavy chain variable domain with an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:1, includes a CDR1 sequence represented by the amino acid sequence of SEQ ID NO:11 or SEQ ID NO:91, a CDR2 sequence represented by the amino acid sequence of SEQ ID NO:12, and a CDR3 sequence represented by the amino acid sequence of SEQ ID NO:13 or 68. In certain embodiments, an antigen-binding site that includes an antibody light chain variable domain with an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:2, includes a CDR1 sequence represented by the amino acid sequence of SEQ ID NO:14, a CDR2 sequence represented by the amino acid sequence of SEQ ID NO:15, and a CDR3 sequence represented by the amino acid sequence of SEQ ID NO:16.
In certain embodiments, the present invention provides an antigen-binding site that includes an antibody heavy chain variable domain that includes an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:3, and an antibody light chain variable domain that includes an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:4. In certain embodiments, an antigen-binding site that includes an antibody heavy chain variable domain with an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:3, includes a CDR1 sequence represented by the amino acid sequence of SEQ ID NO:17 or SEQ ID NO:92, a CDR2 sequence represented by the amino acid sequence of SEQ ID NO:18, and a CDR3 sequence represented by the amino acid sequence of SEQ ID NO:19 or SEQ ID NO:69. In certain embodiments, an antigen-binding site that includes an antibody light chain variable domain with an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:4, includes a CDR1 sequence represented by the amino acid sequence of SEQ ID NO:20, a CDR2 sequence represented by the amino acid sequence of SEQ ID NO:21, and a CDR3 sequence represented by the amino acid sequence of SEQ ID NO:22.
In certain embodiments, the present invention provides an antigen-binding site that includes an antibody heavy chain variable domain that includes an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:5, and an antibody light chain variable domain that includes an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:6. In certain embodiments, an antigen-binding site that includes an antibody heavy chain variable domain with an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:5, includes a CDR1 sequence represented by the amino acid sequence of SEQ ID NO:23 or SEQ ID NO:93, a CDR2 sequence represented by the amino acid sequence of SEQ ID NO:24, and a CDR3 sequence represented by the amino acid sequence of SEQ ID NO:25 or SEQ ID NO:70. In certain embodiments, an antigen-binding site that includes an antibody light chain variable domain with an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:6, includes a CDR1 sequence represented by the amino acid sequence of SEQ ID NO:26, a CDR2 sequence represented by the amino acid sequence of SEQ ID NO:27, and a CDR3 sequence represented by the amino acid sequence of SEQ ID NO:28.
In certain embodiments, the present invention provides an antigen-binding site that includes an antibody heavy chain variable domain that includes an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:7, and an antibody light chain variable domain that includes an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:8. In certain embodiments, an antigen-binding site that includes an antibody heavy chain variable domain with an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:7, includes a CDR1 sequence represented by the amino acid sequence of SEQ ID NO:29 or SEQ ID NO:94, a CDR2 sequence represented by the amino acid sequence of SEQ ID NO:30, and a CDR3 sequence represented by the amino acid sequence of SEQ ID NO:31 or SEQ ID NO:71. In certain embodiments, an antigen-binding site that includes an antibody light chain variable domain with an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:8, includes a CDR1 sequence represented by the amino acid sequence of SEQ ID NO:32, a CDR2 sequence represented by the amino acid sequence of SEQ ID NO:33, and a CDR3 sequence represented by the amino acid sequence of SEQ ID NO:34.
The amino acid residue M at position 102 of SEQ ID NO:7, which is in CDR3 of the heavy chain variable domain, can be mutated. In certain embodiments, M102 is substituted by a non-charged residue. In certain embodiments, M102 is substituted by a hydrophobic residue (Gly, Ala, Val, Leu, Ile, Pro, Phe, or Trp). In certain embodiments, M102 is substituted by a polar residue (Ser, Thr, Cys, Asn, Gln, or Tyr). In certain embodiments, M102 is substituted by Leu, Ile, Val, Gln, or Phe.
Accordingly, in certain embodiments, the present invention provides an antigen-binding site that includes an antibody heavy chain variable domain that includes an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:83, and an antibody light chain variable domain that includes an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:8. In certain embodiments, an antigen-binding site that includes an antibody heavy chain variable domain with an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:83, includes a CDR1 sequence represented by the amino acid sequence of SEQ ID NO:29 or SEQ ID NO:94, a CDR2 sequence represented by the amino acid sequence of SEQ ID NO:30, and a CDR3 sequence represented by the amino acid sequence of SEQ ID NO:73 or SEQ ID NO:74. In certain embodiments, an antigen-binding site that includes an antibody light chain variable domain with an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:8, includes a CDR1 sequence represented by the amino acid sequence of SEQ ID NO:32, a CDR2 sequence represented by the amino acid sequence of SEQ ID NO:33, and a CDR3 sequence represented by the amino acid sequence of SEQ ID NO:34.
In certain embodiments, the present invention provides an antigen-binding site that includes an antibody heavy chain variable domain that includes an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:84, and an antibody light chain variable domain that includes an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:8. In certain embodiments, an antigen-binding site that includes an antibody heavy chain variable domain with an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:84, includes a CDR1 sequence represented by the amino acid sequence of SEQ ID NO:29 or SEQ ID NO:94, a CDR2 sequence represented by the amino acid sequence of SEQ ID NO:30, and a CDR3 sequence represented by the amino acid sequence of SEQ ID NO:75 or SEQ ID NO:76. In certain embodiments, an antigen-binding site that includes an antibody light chain variable domain with an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:8, includes a CDR1 sequence represented by the amino acid sequence of SEQ ID NO:32, a CDR2 sequence represented by the amino acid sequence of SEQ ID NO:33, and a CDR3 sequence represented by the amino acid sequence of SEQ ID NO:34.
In certain embodiments, the present invention provides an antigen-binding site that includes an antibody heavy chain variable domain that includes an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:85, and an antibody light chain variable domain that includes an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:8. In certain embodiments, an antigen-binding site that includes an antibody heavy chain variable domain with an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:85, includes a CDR1 sequence represented by the amino acid sequence of SEQ ID NO:29 or SEQ ID NO:94, a CDR2 sequence represented by the amino acid sequence of SEQ ID NO:30, and a CDR3 sequence represented by the amino acid sequence of SEQ ID NO:77 or SEQ ID NO:78. In certain embodiments, an antigen-binding site that includes an antibody light chain variable domain with an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:8, includes a CDR1 sequence represented by the amino acid sequence of SEQ ID NO:32, a CDR2 sequence represented by the amino acid sequence of SEQ ID NO:33, and a CDR3 sequence represented by the amino acid sequence of SEQ ID NO:34.
In certain embodiments, the present invention provides an antigen-binding site that includes an antibody heavy chain variable domain that includes an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:86, and an antibody light chain variable domain that includes an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:8. In certain embodiments, an antigen-binding site that includes an antibody heavy chain variable domain with an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:86, includes a CDR1 sequence represented by the amino acid sequence of SEQ ID NO:29 or SEQ ID NO:94, a CDR2 sequence represented by the amino acid sequence of SEQ ID NO:30, and a CDR3 sequence represented by the amino acid sequence of SEQ ID NO:79 or 80. In certain embodiments, an antigen-binding site that includes an antibody light chain variable domain with an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:8, includes a CDR1 sequence represented by the amino acid sequence of SEQ ID NO:32, a CDR2 sequence represented by the amino acid sequence of SEQ ID NO:33, and a CDR3 sequence represented by the amino acid sequence of SEQ ID NO:34.
In certain embodiments, the present invention provides an antigen-binding site that includes an antibody heavy chain variable domain that includes an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:41, and an antibody light chain variable domain that includes an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:8. In certain embodiments, an antigen-binding site that includes an antibody heavy chain variable domain with an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:41, includes a CDR1 sequence represented by the amino acid sequence of SEQ ID NO:29 or SEQ ID NO:94, a CDR2 sequence represented by the amino acid sequence of SEQ ID NO:30, and a CDR3 sequence represented by the amino acid sequence of SEQ ID NO:81 or SEQ ID NO:82. In certain embodiments, an antigen-binding site that includes an antibody light chain variable domain with an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:8, includes a CDR1 sequence represented by the amino acid sequence of SEQ ID NO:32, a CDR2 sequence represented by the amino acid sequence of SEQ ID NO:33, and a CDR3 sequence represented by the amino acid sequence of SEQ ID NO:34.
In certain embodiments, the present invention provides an antigen-binding site that includes an antibody heavy chain variable domain that includes an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:9, and an antibody light chain variable domain that includes an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:10. In certain embodiments, an antigen-binding site that includes an antibody heavy chain variable domain with an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:9, includes a CDR1 sequence represented by the amino acid sequence of SEQ ID NO:35 or SEQ ID NO:91, a CDR2 sequence represented by the amino acid sequence of SEQ ID NO:36, and a CDR3 sequence represented by the amino acid sequence of SEQ ID NO:37 or SEQ ID NO:72. In certain embodiments, an antigen-binding site that includes an antibody light chain variable domain with an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:10, includes a CDR1 sequence represented by the amino acid sequence of SEQ ID NO:38, a CDR2 sequence represented by the amino acid sequence of SEQ ID NO:39, and a CDR3 sequence represented by the amino acid sequence of SEQ ID NO:40.
In certain embodiments, the present invention provides an antigen-binding site that includes an antibody heavy chain variable domain that includes an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:5, and an antibody light chain variable domain that includes an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:6, that does not block the binding of anti-NKG2D antibodies MS, 1D11, and MAB139 to NKG2D.
In embodiments, an antigen-binding site that includes an antibody heavy chain variable domain that includes an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:7, 83, 84, 85, 86, or 87, and an antibody light chain variable domain that includes an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:8, does not block binding of an antigen-binding site that includes an antibody heavy chain variable domain that includes an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:5, and an antibody light chain variable domain that includes an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:6 to NKG2D.
In certain embodiments, an antigen-binding site that includes an antibody heavy chain variable domain that includes an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:5, and an antibody light chain variable domain that includes an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:6, binds to a unique epitope on NKG2D, different from MS, 1D11, MAB139, ADI-27749 and F47 binding epitope(s).
Antibodies and Multi-Specific Binding Proteins
In some embodiments of this invention, the NKG2D antigen-binding sites formed by pairing an antibody heavy chain variable domain with a light chain variable domain described herein can be included into larger proteins such as intact antibodies, multi-specific binding proteins or multi-specific binding antibodies. For example, an NKG2D-binding site can be combined with a second component, e.g., a second antigen-binding site. In some embodiments, the second antigen-binding site binds to one or more tumor-associated antigens, such as CD33, HER2, EpCAM, CD2, CD3, CD8, CD10, CD19, CD20, CD21, CD22, CD23, CD24, CD25, CD30, CD33, CD37, CD38, CD40, CD45RO, CD48, CD52, CD55, CD59, CD70, CD74, CD80, CD86, CD138, CD147, HLA-DR, CSAp, CA-125, TAG-72, EFGR/ERBB1, IGF1R, HER3, HER4, IGF-1R, c-Met, PDGFR, MUC1, MUC2, MUC3, MUC4, TNFR1, TNFR2, NGFR, TRAILR1, TRAILR2, Fas (CD95), DR3, DR4, DR5, DR6, VEGF, PIGF, tenascin, ED-B fibronectin, PSA, and IL-6, MAGE-A3, B7.1, B7.2, CTLA4 or PD1. Binding of a multi-specific protein to NKG2D and to a tumor-associated antigen on a cancer cell brings the cancer cell into proximity to the natural killer cell, which facilitates destruction of the cancer cell by the natural killer cell either directly or indirectly.
In some embodiments, in addition to an NKG2D-binding site and a tumor-associated antigen-binding site, a multi-specific binding protein can further include a domain that binds to CD16, an Fc receptor on the surface of leukocytes including natural killer cells, macrophages, neutrophils, eosinophils, mast cells, and follicular dendritic cells. In some embodiments, the CD16 binding domain can include an antibody Fc region or a portion thereof. In some embodiments, the domain that binds to CD16 contains hinge, CH2 and CH3 domains of an antibody Fc region without or without CH1 domain. In some embodiments, the antibody Fc region is derived from the Fc regions in the human and/or other mammalian immunoglobulins. It is known that within the Fc region, CD16 binding is mediated by the hinge region and the CH2 domain. For example, within human IgG1, the interaction with CD16 is mediated through amino acid residues Asp 265-Glu 269, Asn 297-Thr 299, Ala 327-Ile 332, Leu 234-Ser 239, and carbohydrate residue N-acetyl-D-glucosamine in the CH2 domain (see Sondermann et al, Nature, 406(6793):267-273). Based on the known domains and amino acid residues, in some embodiments, mutations can be selected within the CD16 binding domain to enhance or reduce its binding affinity to CD16. Selection methods are well known methods in the art, such as phage-displayed libraries or yeast surface-displayed cDNA libraries. Appropriate selection methods can also be designed based on the known three-dimensional structure of the interaction by a skilled person in the art.
The multi-specific binding proteins described herein can take various formats. For example, one format is a heterodimeric, multi-specific antibody that includes a first immunoglobulin heavy chain, a first immunoglobulin light chain, a second immunoglobulin heavy chain and a second immunoglobulin light chain. The first immunoglobulin heavy chain includes a first Fc (hinge-CH2-CH3) domain, a first heavy chain variable domain and optionally a first CH1 heavy chain domain. The first immunoglobulin light chain includes a first light chain variable domain and a first light chain constant domain. The first immunoglobulin light chain, together with the first immunoglobulin heavy chain, forms an antigen-binding site that binds NKG2D. The second immunoglobulin heavy chain comprises a second Fc (hinge-CH2-CH3) domain, a second heavy chain variable domain and optionally a second CH1 heavy chain domain. The second immunoglobulin light chain includes a second light chain variable domain and a second light chain constant domain. The second immunoglobulin light chain, together with the second immunoglobulin heavy chain, forms an antigen-binding site that binds a tumor antigen. The first Fc domain and second Fc domain together are able to bind to CD16 (
Another exemplary format involves a heterodimeric, multi-specific antibody that includes a first immunoglobulin heavy chain, a second immunoglobulin heavy chain and an immunoglobulin light chain. The first immunoglobulin heavy chain includes a first Fc (hinge-CH2-CH3) domain fused via either a linker or an antibody hinge to a single-chain variable fragment (scFv) composed of a heavy variable domain and light chain variable domain which pair and bind NKG2D. The second immunoglobulin heavy chain includes a second Fc (hinge-CH2-CH3) domain, a second heavy chain variable domain and optionally a CH1 heavy chain domain. The immunoglobulin light chain includes a light chain variable domain and a constant light chain domain. The second immunoglobulin heavy chain pairs with the immunoglobulin light chain and binds to a tumor-associated antigen. The first Fc domain and the second Fc domain together are able to bind to CD16 (
One or more additional binding motifs may be fused to the C-terminus of the constant region CH3 domain, optionally via a linker sequence. In certain embodiments, the antigen-binding site could be a single-chain or disulfide-stabilized variable region (scFv) or could form a tetravalent or trivalent molecule.
In some embodiments, the multi-specific binding protein is in the Triomab form, which is a trifunctional, bispecific antibody that maintains an IgG-like shape. This chimera consists of two half antibodies, each with one light and one heavy chain, that originate from two parental antibodies. Triomab form is an heterodimeric construct containing ½ of rat antibody and ½ of mouse antibody.
In some embodiments, the multi-specific binding protein is the KiH Common Light Chain (LC) form, which involves the knobs-into-holes (KIHs) technology. The KIH involves engineering CH3 domains to create either a “knob” or a “hole” in each heavy chain to promote heterodimerization. The concept behind the “Knobs-into-Holes (KiH)” Fc technology was to introduce a “knob” in one CH3 domain (CH3A) by substitution of a small residue with a bulky one (i.e., T366WCH3A in EU numbering). To accommodate the “knob,” a complementary “hole” surface was created on the other CH3 domain (CH3B) by replacing the closest neighboring residues to the knob with smaller ones (i.e., T366S/L368A/Y407VCH3B). The “hole” mutation was optimized by structured-guided phage library screening (Atwell S, Ridgway J B, Wells J A, Carter P. Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. J Mol Biol (1997) 270(1):26-35). X-ray crystal structures of KiH Fc variants (Elliott J M, Ultsch M, Lee J, Tong R, Takeda K, Spiess C, et al., Antiparallel conformation of knob and hole aglycosylated half-antibody homodimers is mediated by a CH2-CH3 hydrophobic interaction. J Mol Biol (2014) 426(9):1947-57; Mimoto F, Kadono S, Katada H, Igawa T, Kamikawa T, Hattori K. Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcgammaRs. Mol Immunol (2014) 58(1):132-8) demonstrated that heterodimerization is thermodynamically favored by hydrophobic interactions driven by steric complementarity at the inter-CH3 domain core interface, whereas the knob-knob and the hole-hole interfaces do not favor homodimerization owing to steric hindrance and disruption of the favorable interactions, respectively.
In some embodiments, the multi-specific binding protein is in the dual-variable domain immunoglobulin (DVD-Ig™) form, which combines the target binding domains of two monoclonal antibodies via flexible naturally occurring linkers, and yields a tetravalent IgG-like molecule. DVD-Ig™ is an homodimeric construct where variable domain targeting antigen 2 is fused to the N terminus of variable domain of Fab targeting antigen 1 Construct contains normal Fc.
In some embodiments, the multi-specific binding protein is in the Orthogonal Fab interface (Ortho-Fab) form, which is an heterodimeric construct that contains 2 Fabs binding to target 1 and target 2 fused to Fc. LC-HC pairing is ensured by orthogonal interface. Heterodimerization is ensured by mutations in the Fc. In ortho-Fab IgG approach (Lewis S M, Wu X, Pustilnik A, Sereno A, Huang F, Rick H L, et al. Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface. Nat. Biotechnol. (2014) 32(2):191-8), structure-based regional design introduces complementary mutations at the LC and HCVH-CH1 interface in only one Fab, without any changes being made to the other Fab.
In some embodiments, the multi-specific binding protein is in the 2-in-1 Ig format. In some embodiments, the multi-specific binding protein is in the ES form, which is an heterodimeric construct containing 2 different Fabs binding to target 1 and target 2 fused to the Fc. Heterodimerization is ensured by electrostatic steering mutations in the Fc.
In some embodiments, the multi-specific binding protein is in the κλ-Body form, which are an heterodimeric constructs with 2 different Fabs fused to Fc stabilized by heterodimerization mutations: Fab1 targeting antigen 1 contains kappa LC, while second Fab targeting antigen 2 contains lambda LC.
In some embodiments, the multi-specific binding protein is in Fab Arm Exchange form (antibodies that exchange Fab arms by swapping a heavy chain and attached light chain (half-molecule) with a heavy-light chain pair from another molecule, which results in bispecific antibodies). Fab Arm Exchange form (cFae) is a heterodimer containing 2 Fabs binding to target 1 and 2, and an Fc stabilized by heterodimerization mutations.
In some embodiments, the multi-specific binding protein is in the SEED Body form which is an heterodimer containing 2 Fabs binding to target 1 and 2, and an Fc stabilized by heterodimerization mutations. The strand-exchange engineered domain (SEED) platform was designed to generate asymmetric and bispecific antibody-like molecules, a capability that expands therapeutic applications of natural antibodies. This protein engineered platform is based on exchanging structurally related sequences of immunoglobulin within the conserved CH3 domains. The SEED design allows efficient generation of AG/GA heterodimers, while disfavoring homodimerization of AG and GA SEED CH3 domains. (Muda M. et al., Protein Eng. Des. Sel. (2011, 24(5):447-54)).
In some embodiments, the multi-specific binding protein is in the LuZ-Y form, in which leucine zipper is used to induce heterodimerization of two different HCs. (Wranik, B J. et al., J. Biol. Chem. (2012), 287:43331-9). LuZ-Y form is a heterodimer containing 2 different scFabs binding to target 1 and 2, fused to Fc. Heterodimerization is ensured through leucine zipper motifs fused to C-terminus of Fc.
In some embodiments, the multi-specific binding protein is in the Cov-X-Body form (In bispecific CovX-Bodies, two different peptides are joined together using a branched azetidinone linker and fused to the scaffold antibody under mild conditions in a site-specific manner. Whereas the pharmacophores are responsible for functional activities, the antibody scaffold imparts long half-life and Ig-like distribution. The pharmacophores can be chemically optimized or replaced with other pharmacophores to generate optimized or unique bispecific antibodies. (Doppalapudi V R et al., PNAS (2010), 107(52); 22611-22616).
In some embodiments, the multi-specific binding protein is in an Oasc-Fab heterodimeric format that includes Fab binding to target 1 and scFab binding to target 2 fused to Fc. Heterodimerization is ensured by mutations in the Fc.
In some embodiments, the multi-specific binding protein is in an DuetMab format containing 2 different Fabs binding to antigen 1 and 2 and Fc stabilized by heterodimerization mutations. Fab 1 and 2 contain differential S—S bridges that ensure correct LC and HC pairing.
In some embodiments, the multi-specific binding protein is in an CrossmAb format which is an heterodimeric construct with 2 different Fabs binding to Target 1 and 2 fused to Fc stabilized by heterodimerization. CL and CH1 domains and VH and VL domains are switched, e.g. CH1 is fused in-line with VL, while CL is fused in-line with VH.
In some embodiments, the multi-specific binding protein is in an CrossmAb format which is an homodimeric constructs where Fab binding to antigen 2 is fused to the N terminus of HC of Fab that binds to antigen 1.
Heterodimeric Antibody Heavy Chains
Assembly of heterodimeric antibody heavy chains can be accomplished by expressing two different antibody heavy chain sequences in the same cell, which may lead to the assembly of homodimers of each antibody heavy chain as well as assembly of heterodimers. Preferential assembly of heterodimeric heavy chains within the multi-specific binding proteins described herein can be promoted by incorporating distinct pairs of amino acid substitutions into the first CH3 domain within the first heavy chain polypeptide and the second CH3 domain within the second heavy chain polypeptide that allow these two chains to selectively heterodimerize with each other, as shown in U.S. Ser. Nos. 13/494,870, 16/028,850, 11/533,709, 12/875,015, 13/289,934, 14/773,418, 12/811,207, 13/866,756, 14/647,480, 14/830,336. In some embodiments, the multi-specific binding proteins contain the Fc domain of human IgG1. Various examples of amino acid substitutions within the pair of human IgG1 Fc domains are listed below to facilitate heterodimerization of two heavy chains. Each positions of amino acid substitutions is numbered according to the EU index as in Kabat.
In one scenario, an amino acid substitution in the first polypeptide replaces the original amino acid with a larger amino acid, selected from arginine (R), phenylalanine (F), tyrosine (Y) or tryptophan (W), and at least one amino acid substitution in the second polypeptide replaces the original amino acid(s) with a smaller amino acid(s), chosen from alanine (A), serine (S), threonine (T), or valine (V), such that the larger amino acid substitution (a protuberance) fits into the surface of the smaller amino acid substitutions (a cavity). For example, one polypeptide can include a T366W substitution, and the other can include three substitutions including T366S, L368A, and Y407V.
Alternatively, amino acid substitutions could be selected from the following sets of substitutions shown in Table 2.
Alternatively, amino acid substitutions could be selected from the following sets of substitutions shown in Table 3.
Alternatively, amino acid substitutions could be selected from the following set of substitutions shown in Table 4.
Alternatively, at least one amino acid substitution in each polypeptide chain could be selected from Table 5.
Alternatively, at least one amino acid substitutions could be selected from the following set of substitutions in Table 6, where the position(s) indicated in the First Polypeptide column is replaced by any known negatively-charged amino acid, and the position(s) indicated in the Second Polypeptide Column is replaced by any known positively-charged amino acid.
Alternatively, at least one amino acid substitutions could be selected from the following set of in Table 7, where the position(s) indicated in the First Polypeptide column is replaced by any known positively-charged amino acid, and the position(s) indicated in the Second Polypeptide Column is replaced by any known negatively-charged amino acid.
Alternatively, amino acid substitutions could be selected from the following set of in Table 8.
Alternatively, or in addition, the structural stability of heterodimeric heavy chains within the multi-specific binding proteins can be increased by introducing S354C on either of the first or second polypeptide chain, and Y349C on the opposing polypeptide chain, which forms an artificial disulfide bridge within the interface of the two polypeptides.
The multi-specific binding proteins described above can be made using recombinant DNA technology well known to a skilled person in the art. For example, a first nucleic acid sequence encoding the first immunoglobulin heavy chain can be cloned into a first expression vector; a second nucleic acid sequence encoding the second immunoglobulin heavy chain can be cloned into a second expression vector; a third nucleic acid sequence encoding the first immunoglobulin light chain can be cloned into a third expression vector; a fourth nucleic acid sequence encoding the second immunoglobulin light chain can be cloned into a fourth expression vector; the first, second, third and fourth expression vectors can be stably transfected together into host cells to produce the multimeric proteins.
To achieve the highest yield of the multi-specific binding proteins, different ratios of the first, second, third and fourth expression vectors can be explored to determine the optimal ratio for transfection into the host cells. After transfection, single clones can be isolated for cell bank generation using methods known in the art, such as limited dilution, ELISA, FACS, microscopy, or Clonepix.
Clones can be cultured under conditions suitable for bio-reactor scale-up and maintained expression of the multi-specific protein. The multi-specific binding proteins can be isolated and purified using methods known in the art including centrifugation, depth filtration, cell lysis, homogenization, freeze-thawing, affinity purification, gel filtration, ion exchange chromatography, hydrophobic interaction exchange chromatography, and mixed-mode chromatography.
A Protein Comprising an Antigen-Binding Site that Competes with the NKG2D-Binding Sites Described Herein
In certain embodiments, the present invention provides a protein that includes an antigen-binding site that competes with the NKG2D-binding sites described herein to bind to NKG2D. The NKG2D-binding sites described herein comprises amino acid sequences of SEQ ID NOs: 1 and 2; amino acid sequences of SEQ ID NOs: 3 and 4; amino acid sequences of SEQ ID NOs: 5 and 6; amino acid sequences of SEQ ID NOs: 7 and 8; amino acid sequences of SEQ ID NOs: 9 and 10; amino acid sequences of SEQ ID NOs: 83 and 8; amino acid sequences of SEQ ID NOs: 84 and 8; amino acid sequences of SEQ ID NOs: 85 and 8; amino acid sequences of SEQ ID NOs: 86 and 8; or amino acid sequences of SEQ ID NOs: 87 and 8. These NKG2D-binding sites can bind to different epitopes on NKG2D mapped by surface plasmon resonance. For example, ADI-27744 binds to a different epitope on NKG2D from ADI-27749 and other existing NKG2D antibodies, as shown in Example 2.
In some embodiments, an antigen-binding site of the protein that competes with the NKG2D-binding sites includes a heavy chain variable domain having an amino acid sequence at least 50% (e.g., 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:1 and a light chain variable domain having an amino acid sequence at least at least 50% (e.g., 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:2. In some embodiments, an antigen-binding site of the protein that competes with the NKG2D-binding sites includes a heavy chain variable domain having an amino acid sequence at least at least 50% (e.g., 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:3 and a light chain variable domain having an amino acid sequence at least at least 50% (e.g., 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:4. In some embodiments, an antigen-binding site of the protein that competes with the NKG2D-binding sites includes a heavy chain variable domain having an amino acid sequence at least at least 50% (e.g., 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:5 and a light chain variable domain having an amino acid sequence at least at least 50% (e.g., 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:6. In some embodiments, an antigen-binding site of the protein that competes with the NKG2D-binding sites includes a heavy chain variable domain having an amino acid sequence at least at least 50% (e.g., 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:7 and a light chain variable domain having an amino acid sequence at least at least 50% (e.g., 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:8. In some embodiments an antigen-binding site of the protein that competes with the NKG2D-binding sites includes a heavy chain variable domain having an amino acid sequence at least at least 50% (e.g., 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:9 and a light chain variable domain having an amino acid sequence at least at least 50% (e.g., 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:10.
In some embodiments, the protein that includes an antigen-binding site that competes with NKG2D-binding sites described herein further includes a second antigen-binding site that binds a tumor-associated antigen and/or a CD16 binding site. In some embodiments, the CD16 binding site is an antibody constant region or a portion thereof capable of binding CD16. In some embodiments, the CD16 binding site contains a human IgG1 Fc domain.
Cell for Expressing a Protein
In one aspect, the present disclosure provides a cell comprising one or more nucleic acids encoding a protein that contains: an NKG2D-binding site with a heavy chain variable domain having an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:1, and a light chain variable domain having an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:2; a NKG2D-binding site with a heavy chain variable domain having an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:3, and a light chain variable domain having an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:4; an NKG2D-binding site with a heavy chain variable domain having an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:5, and a light chain variable domain having an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:6; an NKG2D-binding site with a heavy chain variable domain having an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:7, 83, 84, 85, 86, or 87, and a light chain variable domain having an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:8; or an NKG2D-binding site with a heavy chain variable domain having an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:9, and a light chain variable domain having an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:10.
Therapeutic Applications
The invention provides methods for enhancing tumor cell death and/or treating cancer using a multi-specific binding protein described herein and/or a pharmaceutical composition described herein. The methods may be used to treat a variety of cancers. The type of cancer to be treated is desirably matched with the type of cancer cell to which the protein binds. Additional aspects and embodiments of the therapeutic methods are described below.
Pharmaceutical Compositions
In one aspect, the present disclosure also features pharmaceutical compositions that contain an effective amount of a protein, which contains an NKG2D-binding site described herein or an NKG2D-binding site that competes with the NKG2D-binding sites described herein, and a pharmaceutically acceptable carrier.
In certain embodiments, the formulation includes a protein that comprises an antigen-binding site with a heavy chain variable domain having an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:1, and a light chain variable domain having an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:2. In certain embodiments, the formulation includes a protein that includes an antigen-binding site with a heavy chain variable domain having an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:3, and a light chain variable domain having an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:4. In certain embodiments, the formulation includes a protein that includes an antigen-binding site with a heavy chain variable domain having an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:5, and a light chain variable domain having an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:6. In certain embodiments, the formulation includes a protein that includes an antigen-binding site with a heavy chain variable domain having an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:7, 83, 84, 85, 86, or 87, and a light chain variable domain having an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:8. In certain embodiments, the formulation includes a protein that includes an antigen-binding site with a heavy chain variable domain having an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:9, and a light chain variable domain having an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:10.
The composition can be formulated for use in a variety of drug delivery systems. One or more physiologically acceptable excipients or carriers can be included in the composition for proper formulation. Suitable formulations for use in the present disclosure are found in Remington's Pharmaceutical Sciences, Mack Publishing Company, Philadelphia, Pa., 17th ed., 1985. For a brief review of methods for drug delivery, see, e.g., Langer (Science 249:1527-1533, 1990).
For example, this present disclosure could exist in an aqueous pharmaceutical formulation including a therapeutically effective amount of the protein in a buffered solution forming a formulation. Aqueous carriers can include sterile water for injection (SWFI), bacteriostatic water for injection (BWFI), a pH buffered solution (e.g. phosphate-buffered saline), sterile saline solution, Ringer's solution or dextrose solution. In certain embodiments, an aqueous formulation is prepared including the protein disclosed herein in a pH-buffered solution. The pH of the preparations typically will be between 3 and 11, more preferably between 5 and 9 or between 6 and 8, and most preferably between 7 and 8, such as 7 to 7.5. Ranges intermediate to the above recited pH's are also intended to be part of this disclosure. For example, ranges of values using a combination of any of the above recited values as upper and/or lower limits are intended to be included. Examples of buffers that will control the pH within this range include acetate (e.g. sodium acetate), succinate (such as sodium succinate), gluconate, histidine, citrate and other organic acid buffers. In certain embodiments, the buffer system includes citric acid monohydrate, sodium citrate, disodium phosphate dihydrate, and/or sodium dihydrogen phosphate dihydrate. In certain embodiments, the buffer system includes about 1.3 mg/ml of citric acid (e.g., 1.305 mg/ml), about 0.3 mg/ml of sodium citrate (e.g., 0.305 mg/ml), about 1.5 mg/ml of disodium phosphate dihydrate (e.g. 1.53 mg/ml), about 0.9 mg/ml of sodium dihydrogen phosphate dihydrate (e.g., 0.86), and about 6.2 mg/ml of sodium chloride (e.g., 6.165 mg/ml). In certain embodiments, the buffer system includes 1-1.5 mg/ml of citric acid, 0.25 to 0.5 mg/ml of sodium citrate, 1.25 to 1.75 mg/ml of disodium phosphate dihydrate, 0.7 to 1.1 mg/ml of sodium dihydrogen phosphate dihydrate, and 6.0 to 6.4 mg/ml of sodium chloride. The pH of the liquid formulation may be set by addition of a pharmaceutically acceptable acid and/or base. In certain embodiments, the pharmaceutically acceptable acid may be hydrochloric acid. In certain embodiments, the base may be sodium hydroxide.
In some embodiments, the formulation includes an aqueous carrier, which is pharmaceutically acceptable (safe and non-toxic for administration to a human) and is useful for the preparation of a liquid formulation. Illustrative carriers include sterile water for injection (SWFI), bacteriostatic water for injection (BWFI), a pH buffered solution (e.g. phosphate-buffered saline), sterile saline solution, Ringer's solution or dextrose solution.
A polyol, which acts as a tonicifier and may stabilize the antibody, may also be included in the formulation. The polyol is added to the formulation in an amount which may vary with respect to the desired isotonicity of the formulation. In certain embodiments, the aqueous formulation may be isotonic. The amount of polyol added may also be altered with respect to the molecular weight of the polyol. For example, a lower amount of a monosaccharide (e.g. mannitol) may be added, compared to a disaccharide (such as trehalose). In certain embodiments, the polyol which may be used in the formulation as a tonicity agent is mannitol. In certain embodiments, the mannitol concentration may be about 5 to about 20 mg/ml. In certain embodiments, the concentration of mannitol may be about 7.5 to 15 mg/ml. In certain embodiments, the concentration of mannitol may be about 10-14 mg/ml. In certain embodiments, the concentration of mannitol may be about 12 mg/ml. In certain embodiments, the polyol sorbitol may be included in the formulation.
A detergent or surfactant may also be added to the formulation. Exemplary detergents include nonionic detergents such as polysorbates (e.g. polysorbates 20, 80 etc.) or poloxamers (e.g., poloxamer 188). The amount of detergent added is such that it reduces aggregation of the formulated antibody and/or minimizes the formation of particulates in the formulation and/or reduces adsorption. In certain embodiments, the formulation may include a surfactant which is a polysorbate. In certain embodiments, the formulation may contain the detergent polysorbate 80 or Tween 80. Tween 80 is a term used to describe polyoxyethylene (20) sorbitanmonooleate (see Fiedler, Lexikon der Hifsstoffe, Editio Cantor Verlag Aulendorf, 4th edi., 1996). In certain embodiments, the formulation may contain between about 0.1 mg/mL and about 10 mg/mL of polysorbate 80, or between about 0.5 mg/mL and about 5 mg/mL. In certain embodiments, about 0.1% polysorbate 80 may be added in the formulation.
In certain embodiments, the liquid formulation of the disclosure may be prepared as a 10 mg/mL concentration solution in combination with a sugar at stabilizing levels. In certain embodiments the liquid formulation may be prepared in an aqueous carrier. In certain embodiments, a stabilizer may be added in an amount no greater than that which may result in a viscosity undesirable or unsuitable for intravenous administration. In certain embodiments, the sugar may be disaccharides, e.g., sucrose. In certain embodiments, the liquid formulation may also include one or more of a buffering agent, a surfactant, and a preservative, which is added to the formulations herein to reduce bacterial action. The addition of a preservative may, for example, facilitate the production of a multi-use (multiple-dose) formulation.
In some embodiments, the present disclosure provides a formulation with an extended shelf life including the protein of the present disclosure, in combination with mannitol, citric acid monohydrate, sodium citrate, disodium phosphate dihydrate, sodium dihydrogen phosphate dihydrate, sodium chloride, polysorbate 80, water, and sodium hydroxide.
Deamidation is a common product variant of peptides and proteins that may occur during fermentation, harvest/cell clarification, purification, drug substance/drug product storage and during sample analysis. Deamidation is the loss of NH3 from a protein forming a succinimide intermediate that can undergo hydrolysis. The succinimide intermediate results in a mass decrease of 17 Da from the parent peptide. The subsequent hydrolysis results in an 18 u mass increase. Isolation of the succinimide intermediate is difficult due to instability under aqueous conditions. As such, deamidation is typically detectable as 1 u mass increase. Deamidation of an asparagine results in either aspartic or isoaspartic acid. The parameters affecting the rate of deamidation include pH, temperature, solvent dielectric constant, ionic strength, primary sequence, local polypeptide conformation and tertiary structure. The amino acid residues adjacent to Asn in the peptide chain affect deamidation rates. Gly and Ser following an Asn in protein sequences results in a higher susceptibility to deamidation. In certain embodiments, the liquid formulation of the present disclosure may be preserved under conditions of pH and humidity to prevent deamination of the protein product.
In some embodiment, the formulation is a lyophilized formulation. In certain embodiments, the formulation is freeze-dried (lyophilized) and contained in about 12-60 vials. In certain embodiments, the formulation is freeze-dried and 45 mg of the freeze-dried formulation may be contained in one vial. In certain embodiments, the about 40 mg-about 100 mg of freeze-dried formulation is contained in one vial. In certain embodiments, freeze dried formulation from 12, 27, or 45 vials are combined to obtained a therapeutic dose of the protein in the intravenous drug formulation. The formulation may be a liquid formulation. In some embodiments, a liquid formulation is stored as about 250 mg/vial to about 1000 mg/vial. In certain embodiments, the liquid formulation is stored as about 600 mg/vial. In certain embodiments, the liquid formulation is stored as about 250 mg/vial.
In some embodiments, the lyophilized formulation includes the proteins described herein and a lyoprotectant. The lyoprotectant may be sugar, e.g., disaccharides. In certain embodiments, the lycoprotectant may be sucrose or maltose. The lyophilized formulation may also include one or more of a buffering agent, a surfactant, a bulking agent, and/or a preservative. The amount of sucrose or maltose useful for stabilization of the lyophilized drug product may be in a weight ratio of at least 1:2 protein to sucrose or maltose. In certain embodiments, the protein to sucrose or maltose weight ratio may be of from 1:2 to 1:5.
In certain embodiments, the pH of the formulation, prior to lyophilization, may be set by addition of a pharmaceutically acceptable acid and/or base. In certain embodiments the pharmaceutically acceptable acid may be hydrochloric acid. In certain embodiments, the pharmaceutically acceptable base may be sodium hydroxide. Before lyophilization, the pH of the solution containing the protein of the present disclosure may be adjusted between 6 to 8. In certain embodiments, the pH range for the lyophilized drug product may be from 7 to 8.
In certain embodiments, a “bulking agent” may be added. A “bulking agent” is a compound which adds mass to a lyophilized mixture and contributes to the physical structure of the lyophilized cake (e.g., facilitates the production of an essentially uniform lyophilized cake which maintains an open pore structure). Illustrative bulking agents include mannitol, glycine, polyethylene glycol and sorbitol. The lyophilized formulations of the present invention may contain such bulking agents.
In certain embodiments, the lyophilized protein product is constituted with an aqueous carrier. The aqueous carrier of interest herein is one which is pharmaceutically acceptable (e.g., safe and non-toxic for administration to a human) and is useful for the preparation of a liquid formulation, after lyophilization. Illustrative diluents include sterile water for injection (SWFI), bacteriostatic water for injection (BWFI), a pH buffered solution (e.g. phosphate-buffered saline), sterile saline solution, Ringer's solution or dextrose solution. In certain embodiments, the lyophilized drug product of the current disclosure is reconstituted with either Sterile Water for Injection, USP (SWFI) or 0.9% Sodium Chloride Injection, USP. During reconstitution, the lyophilized powder dissolves into a solution. In certain embodiments, the lyophilized protein product of the instant disclosure is constituted to about 4.5 mL water for injection and diluted with 0.9% saline solution (sodium chloride solution).
The protein compositions may be sterilized by conventional sterilization techniques, or may be sterile filtered. The resulting aqueous solutions may be packaged for use as-is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration. The resulting compositions in solid form may be packaged in multiple single dose units, each containing a fixed amount of the above-mentioned agent or agents. The composition in solid form can also be packaged in a container for a flexible quantity.
Actual dosage levels of the active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
The specific dose can be a uniform dose for each patient, for example, 50-5000 mg of protein. Alternatively, a patient's dose can be tailored to the approximate body weight or surface area of the patient. Other factors in determining the appropriate dosage can include the disease or condition to be treated or prevented, the severity of the disease, the route of administration, and the age, sex and medical condition of the patient. Further refinement of the calculations necessary to determine the appropriate dosage for treatment is routinely made by those skilled in the art, especially in light of the dosage information and assays disclosed herein. The dosage can also be determined through the use of known assays for determining dosages used in conjunction with appropriate dose-response data. An individual patient's dosage can be adjusted as the progress of the disease is monitored. Blood levels of the targetable construct or complex in a patient can be measured to see if the dosage needs to be adjusted to reach or maintain an effective concentration. Pharmacogenomics may be used to determine which targetable constructs and/or complexes, and dosages thereof, are most likely to be effective for a given individual (Schmitz et al., Clinica Chimica Acta 308: 43-53, 2001; Steimer et al., Clinica Chimica Acta 308: 33-41, 2001).
In general, dosages based on body weight are from about 0.01 μg to about 100 mg per kg of body weight, such as about 0.01 μg to about 100 mg/kg of body weight, about 0.01 μg to about 50 mg/kg of body weight, about 0.01 μg to about 10 mg/kg of body weight, about 0.01 μg to about 1 mg/kg of body weight, about 0.01 μg to about 100 μg/kg of body weight, about 0.01 μg to about 50 μg/kg of body weight, about 0.01 μg to about 10 μg/kg of body weight, about 0.01 μg to about 1 μg/kg of body weight, about 0.01 μg to about 0.1 μg/kg of body weight, about 0.1 μg to about 100 mg/kg of body weight, about 0.1 μg to about 50 mg/kg of body weight, about 0.1 μg to about 10 mg/kg of body weight, about 0.1 μg to about 1 mg/kg of body weight, about 0.1 μg to about 100 μg/kg of body weight, about 0.1 μg to about 10 μg/kg of body weight, about 0.1 μg to about 1 μg/kg of body weight, about 1 μg to about 100 mg/kg of body weight, about 1 μg to about 50 mg/kg of body weight, about 1 μg to about 10 mg/kg of body weight, about 1 μg to about 1 mg/kg of body weight, about 1 μg to about 100 μg/kg of body weight, about 1 μg to about 50 μg/kg of body weight, about 1 μg to about 10 μg/kg of body weight, about 10 μg to about 100 mg/kg of body weight, about 10 μg to about 50 mg/kg of body weight, about 10 μg to about 10 mg/kg of body weight, about 10 μg to about 1 mg/kg of body weight, about 10 μg to about 100 μg/kg of body weight, about 10 μg to about 50 μg/kg of body weight, about 50 μg to about 100 mg/kg of body weight, about 50 μg to about 50 mg/kg of body weight, about 50 μg to about 10 mg/kg of body weight, about 50 μg to about 1 mg/kg of body weight, about 50 μg to about 100 μg/kg of body weight, about 100 μg to about 100 mg/kg of body weight, about 100 μg to about 50 mg/kg of body weight, about 100 μg to about 10 mg/kg of body weight, about 100 μg to about 1 mg/kg of body weight, about 1 mg to about 100 mg/kg of body weight, about 1 mg to about 50 mg/kg of body weight, about 1 mg to about 10 mg/kg of body weight, about 10 mg to about 100 mg/kg of body weight, about 10 mg to about 50 mg/kg of body weight, about 50 mg to about 100 mg/kg of body weight. Doses may be given once or more times daily, weekly, monthly or yearly, or even once every 2 to 20 years. Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the targetable construct or complex in bodily fluids or tissues. Administration of the present invention could be intravenous, intraarterial, intraperitoneal, intramuscular, subcutaneous, intrapleural, intrathecal, intracavitary, by perfusion through a catheter or by direct intralesional injection. This may be administered once or more times daily, once or more times weekly, once or more times monthly, and once or more times annually.
Enhancing Tumor Cell Death and Cancer Treatment
The invention provides methods of enhancing tumor cell death and/or treating cancer in patient. In some embodiments, the method comprises exposing a tumor and natural killer cells to a multi-specific binding protein disclosed herein. In some embodiments, the method includes administering to a patient in need thereof a therapeutically effective amount of a protein and or its desired formulation described herein. In those embodiments, the multi-specific binding protein can contain: an antigen-binding site with a heavy chain variable domain having an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:1, and a light chain variable domain having an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:2; an antigen-binding site with a heavy chain variable domain having an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:3 and a light chain variable domain having an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:4; an antigen-binding site with a heavy chain variable domain having an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:5 and a light chain variable domain having an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:6; an antigen-binding site with a heavy chain variable domain having an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:7, 83, 84, 85, 86, or 87 and a light chain variable domain having an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:8; or an antigen-binding site with a heavy chain variable domain having an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:9 and a light chain variable domain having an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:10.
The type of cancer to be treated is desirably matched with the type of cancer cell to which the multi-specific binding protein disclosed herein binds. For example, treatment of a cancer expressing epithelial cell adhesion molecule (EpCAM), such as a colon cancer expressing EpCAM, is desirably treated using a multispecific-binding protein described herein that binds to EpCAM and NKG2D.
In some embodiment, patients to be treated contain cancer cells that expresses one or more of the following: CD33, HER2, CD2, CD19, CD20, CD30, CD38, CD40, CD52, CD70, EGFR/ERBB1, IGF1R, HER3/ERBB3, HER4/ERBB4, MUC1, CEA, cMET, SLAMF7, PSCA, MICA, MICB, TRAILR1, TRAILR2, MAGE-A3, B7.1, B7.2, CTLA4, and PD1. In some embodiments, the patients to be treated have a solid cancer, such as brain cancer, bladder cancer, breast cancer, cervical cancer, colon cancer, colorectal cancer, endometrial cancer, esophageal cancer, leukemia, lung cancer, liver cancer, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, renal cancer, stomach cancer, testicular cancer, or uterine cancer. In yet other embodiments, the cancer is a vascularized tumor, squamous cell carcinoma, adenocarcinoma, small cell carcinoma, melanoma, glioma, neuroblastoma, sarcoma (e.g., an angiosarcoma or chondrosarcoma), larynx cancer, parotid cancer, bilary tract cancer, thyroid cancer, acral lentiginous melanoma, actinic keratoses, acute lymphocytic leukemia, acute myeloid leukemia, adenoid cystic carcinoma, adenomas, adenosarcoma, adenosquamous carcinoma, anal canal cancer, anal cancer, anorectum cancer, astrocytic tumor, bartholin gland carcinoma, basal cell carcinoma, biliary cancer, bone cancer, bone marrow cancer, bronchial cancer, bronchial gland carcinoma, carcinoid, cholangiocarcinoma, chondosarcoma, choriod plexus papilloma/carcinoma, chronic lymphocytic leukemia, chronic myeloid leukemia, clear cell carcinoma, connective tissue cancer, cystadenoma, digestive system cancer, duodenum cancer, endocrine system cancer, endodermal sinus tumor, endometrial hyperplasia, endometrial stromal sarcoma, endometrioid adenocarcinoma, endothelial cell cancer, ependymal cancer, epithelial cell cancer, Ewing's sarcoma, eye and orbit cancer, female genital cancer, focal nodular hyperplasia, gallbladder cancer, gastric antrum cancer, gastric fundus cancer, gastrinoma, glioblastoma, glucagonoma, heart cancer, hemangiblastomas, hemangioendothelioma, hemangiomas, hepatic adenoma, hepatic adenomatosis, hepatobiliary cancer, hepatocellular carcinoma, Hodgkin's disease, ileum cancer, insulinoma, intaepithelial neoplasia, interepithelial squamous cell neoplasia, intrahepatic bile duct cancer, invasive squamous cell carcinoma, jejunum cancer, joint cancer, Kaposi's sarcoma, pelvic cancer, large cell carcinoma, large intestine cancer, leiomyosarcoma, lentigo maligna melanomas, lymphoma, male genital cancer, malignant melanoma, malignant mesothelial tumors, medulloblastoma, medulloepithelioma, meningeal cancer, mesothelial cancer, metastatic carcinoma, mouth cancer, mucoepidermoid carcinoma, multiple myeloma, muscle cancer, nasal tract cancer, nervous system cancer, neuroepithelial adenocarcinoma nodular melanoma, non-epithelial skin cancer, non-Hodgkin's lymphoma, oat cell carcinoma, oligodendroglial cancer, oral cavity cancer, osteosarcoma, papillary serous adenocarcinoma, penile cancer, pharynx cancer, pituitary tumors, plasmacytoma, pseudosarcoma, pulmonary blastoma, rectal cancer, renal cell carcinoma, respiratory system cancer, retinoblastoma, rhabdomyosarcoma, sarcoma, serous carcinoma, sinus cancer, skin cancer, small cell carcinoma, small intestine cancer, smooth muscle cancer, soft tissue cancer, somatostatin-secreting tumor, spine cancer, squamous cell carcinoma, striated muscle cancer, submesothelial cancer, superficial spreading melanoma, T cell leukemia, tongue cancer, undifferentiated carcinoma, ureter cancer, urethra cancer, urinary bladder cancer, urinary system cancer, uterine cervix cancer, uterine corpus cancer, uveal melanoma, vaginal cancer, verrucous carcinoma, VIPoma, vulva cancer, well differentiated carcinoma, or Wilms tumor.
In some embodiments, the patients to be treated have non-Hodgkin's lymphoma, such as a B-cell lymphoma or a T-cell lymphoma. In certain embodiments, the non-Hodgkin's lymphoma is a B-cell lymphoma, such as a diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, follicular lymphoma, small lymphocytic lymphoma, mantle cell lymphoma, marginal zone B-cell lymphoma, extranodal marginal zone B-cell lymphoma, nodal marginal zone B-cell lymphoma, splenic marginal zone B-cell lymphoma, Burkitt lymphoma, lymphoplasmacytic lymphoma, hairy cell leukemia, or primary central nervous system (CNS) lymphoma. In certain other embodiments, the non-Hodgkin's lymphoma is a T-cell lymphoma, such as a precursor T-lymphoblastic lymphoma, peripheral T-cell lymphoma, cutaneous T-cell lymphoma, angioimmunoblastic T-cell lymphoma, extranodal natural killer/T-cell lymphoma, enteropathy type T-cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma, anaplastic large cell lymphoma, or peripheral T-cell lymphoma.
In some embodiments, proteins described herein are used in combination with additional therapeutic agents to treat patients with cancer. Exemplary therapeutic agents that may be used as part of a combination therapy in treating cancer, include, for example, radiation, mitomycin, tretinoin, ribomustin, gemcitabine, vincristine, etoposide, cladribine, mitobronitol, methotrexate, doxorubicin, carboquone, pentostatin, nitracrine, zinostatin, cetrorelix, letrozole, raltitrexed, daunorubicin, fadrozole, fotemustine, thymalfasin, sobuzoxane, nedaplatin, cytarabine, bicalutamide, vinorelbine, vesnarinone, aminoglutethimide, amsacrine, proglumide, elliptinium acetate, ketanserin, doxifluridine, etretinate, isotretinoin, streptozocin, nimustine, vindesine, flutamide, drogenil, butocin, carmofur, razoxane, sizofilan, carboplatin, mitolactol, tegafur, ifosfamide, prednimustine, picibanil, levamisole, teniposide, improsulfan, enocitabine, lisuride, oxymetholone, tamoxifen, progesterone, mepitiostane, epitiostanol, formestane, interferon-alpha, interferon-2 alpha, interferon-beta, interferon-gamma, colony stimulating factor-1, colony stimulating factor-2, denileukin diftitox, interleukin-2, luteinizing hormone releasing factor and variations of the aforementioned agents that may exhibit differential binding to its cognate receptor, and increased or decreased serum half-life.
An additional class of agents that may be used as part of a combination therapy in treating cancer is immune checkpoint inhibitors. Exemplary immune checkpoint inhibitors include agents that inhibit one or more of (i) cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), (ii) programmed cell death protein 1 (PD1), (iii) PDL1, (iv) LAG3, (v) B7-H3, (vi) B7-H4, and (vii) TIM3. The CTLA4 inhibitor ipilimumab has been approved by the United States Food and Drug Administration for treating melanoma.
Yet other agents that may be used as part of a combination therapy in treating cancer are monoclonal antibody agents that target non-checkpoint targets (e.g., herceptin) and non-cytotoxic agents (e.g., tyrosine-kinase inhibitors).
Yet other categories of anti-cancer agents include, for example: (i) an inhibitor selected from an ALK Inhibitor, an ATR Inhibitor, an A2A Antagonist, a Base Excision Repair Inhibitor, a Bcr-Abl Tyrosine Kinase Inhibitor, a Bruton's Tyrosine Kinase Inhibitor, a CDC7 Inhibitor, a CHK1 Inhibitor, a Cyclin-Dependent Kinase Inhibitor, a DNA-PK Inhibitor, an Inhibitor of both DNA-PK and mTOR, a DNMT1 Inhibitor, a DNMT1 Inhibitor plus 2-chloro-deoxyadenosine, an HDAC Inhibitor, a Hedgehog Signaling Pathway Inhibitor, an IDO Inhibitor, a JAK Inhibitor, a mTOR Inhibitor, a MEK Inhibitor, a MELK Inhibitor, a MTH1 Inhibitor, a PARP Inhibitor, a Phosphoinositide 3-Kinase Inhibitor, an Inhibitor of both PARP1 and DHODH, a Proteasome Inhibitor, a Topoisomerase-II Inhibitor, a Tyrosine Kinase Inhibitor, a VEGFR Inhibitor, and a WEE1 Inhibitor; (ii) an agonist of OX40, CD137, CD40, GITR, CD27, HVEM, TNFRSF25, or ICOS; and (iii) a cytokine selected from IL-12, IL-15, GM-CSF, and G-CSF.
Proteins of the invention can also be used as an adjunct to surgical removal of the primary lesion.
The amount of protein and additional therapeutic agent and the relative timing of administration may be selected in order to achieve a desired combined therapeutic effect. For example, when administering a combination therapy to a patient in need of such administration, the therapeutic agents in the combination, or a pharmaceutical composition or compositions comprising the therapeutic agents, may be administered in any order such as, for example, sequentially, concurrently, together, simultaneously and the like. Further, for example, a protein described herein may be administered during a time when the additional therapeutic agent(s) exerts its prophylactic or therapeutic effect, or vice versa.
The description above describes multiple aspects and embodiments of the invention. The patent application specifically contemplates all combinations and permutations of the aspects and embodiments.
The invention now being generally described, will be more readily understood by reference to the following examples, which are included merely for purposes of illustration of certain aspects and embodiments of the present invention, and is not intended to limit the invention.
Kinetics and affinity of various NKG2D-binding domains were assessed by surface plasmon resonance using Biacore 8K instrument (GE Healthcare). Anti-human Fc antibody was immobilized on a CM5 chip using standard amine coupling chemistry. Human monoclonal antibodies containing various NKG2D-binding domains were captured on the anti-human Fc chip at a density of approximately 100 RU. Solutions containing 0.411-100 nM soluble mouse Fc-human NKG2D dimers were injected over the captured NKG2D antibodies and control surfaces at 30 μl/min at 37° C. Surfaces were regenerated between cycles by quick injection of 10 mM glycine, pH 1.8. To obtain kinetic rate constants, double-referenced data were fit to a 1:1 interaction model using Biacore 8K Evaluation software (GE Healthcare). The equilibrium binding constant KD was determined by the ratio of dissociation constant kd and association constant ka (kd/ka) As shown in Table 9 and
The binning of ADI-27744 (A44) NKG2D-binding domain was performed against a series of antibodies and ULBP6 (NKG2D natural ligand) by surface plasmon resonance using a Biacore 8K instrument. Briefly, mouse Fc-human NKG2D was captured using an anti-mouse Fc antibody immobilized on a CM5 chip at a density of approximately 100 RU. This was followed by consecutive injections of antibodies, including an NKG2D monoclonal antibody comprising ADI-27744, ADI-27749, F47 (sequences listed below) or 1D11 (a commercial monoclonal NKG2D antibody), ULBP6 (sequence listed below), MS (NKG2D antibody from Novo Nordisk, sequences listed below), and MAB139 (NKG2D antibody from R&D system, clone 149810) at 30 μl/min at 25° C. Biacore 8K evaluation software was used for all data analysis.
ULBP Amino Acid Sequence SEQ ID NO:67:
EL4 mouse lymphoma cell lines were engineered to express human NKG2D. Trispecific binding proteins (TriNKETs) that each contain an NKG2D-binding domain, a tumor-associated antigen-binding domain (such as a CD33 or a HER2-binding domain), and an Fc domain that binds to CD16 as shown in
TriNKETs tested include CD33-TriNKET-A44 (ADI-27744 and a CD33 binding domain), CD33-TriNKET-A49 (ADI-27749 and a CD33 binding domain), CD33-TriNKET-F63 (ADI-29463 and a CD33 binding domain), HER2-TriNKET-A44 (ADI-27744 and a CD33 binding domain), HER2-TriNKET-A49 (ADI-27749 and a HER2 binding domain), HER2-TriNKET-F63 (ADI-29463 and a HER-binding domain), and HER2-TriNKET-E79 (ADI-29379 and a HER2 binding domain). The HER2-binding domain is composed of a heavy chain variable domain and a light chain variable domain of Trastuzumab. The CD33 binding domain is composed of a heavy chain variable domain and a light chain variable domain listed below.
YINPYNDGTKYNEKFKGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAR
DYRYEVYGMDYWGQGTLVTVSS
DTSKVASGVPARFSGSGSGTDFTLTINPVEANDTANYYCQQWRSYPLT
All TriNKETs bind NKG2D on EL4 cells, but with different affinities. CD33-TriNKET-A44 show the same binding profile as HER2-TriNKET-A44, so do CD33-TriNKET-A49 as HER2-TriNKET-A49, and CD33-TriNKET-F63 to HER2-TriNKET-F63. The NKG2D-binding affinity for each clone was similar between cells expressing human and mouse NKG2D (
Trispecific Binding Proteins Bind to CD33
Human AML cell line MV4-11, expressing CD33 was used to assay the binding of TriNKETs to the tumor-associated antigen. TriNKETs and the parental CD33 monoclonal antibody were incubated with the cells, and the binding was detected using fluorophore-conjugated anti-human IgG secondary antibodies. Cells were analyzed by flow cytometry, and fold-over-background (FOB) was calculated using the mean fluorescence intensity (MFI) from TriNKETs and the parental monoclonal CD33 antibody normalized to secondary antibody controls.
CD33-TriNKET-A44, CD33-TriNKET-A49, and CD33-TriNKET-F63 show comparable levels of binding to CD33 as compared with the parental CD33 antibody (
Trispecific Binding Proteins Bind to HER2
Human cancer cell lines expressing HER2 were used to assay the binding of TriNKETs to the tumor-associated antigen. Renal cell carcinoma cell line 786-O expresses low level of HER2, and human lung cancer cell line NCI-H661 expresses moderate levels of HER2. TriNKETs and optionally the parental HER2 monoclonal antibody (Trastuzumab) were incubated with the cells, and the binding was detected using fluorophore-conjugated anti-human IgG secondary antibodies. Cells were analyzed by flow cytometry, and fold-over-background (FOB) was calculated using the mean fluorescence intensity (MFI) from TriNKETs and Trastuzumab normalized to secondary antibody controls.
HER2-TriNKET-A44, HER2-TriNKET-A49, and HER2-TriNKET-F63 show comparable levels of binding to HER2 expressed on 786-O cells as compared with Trastuzumab (
Peripheral blood mononuclear cells (PBMCs) were isolated from human peripheral blood buffy coats using density gradient centrifugation. NK cells (CD3−CD56+) were isolated using negative selection with magnetic beads from PBMCs, and the purity of the isolated NK cells was typically >90%. Isolated NK cells were cultured in media containing 100 ng/mL IL-2 for activation or rested overnight without cytokine. IL-2-activated NK cells were used within 24-48 hours after activation.
Human cancer cells expressing a tumor antigen were harvested and resuspended in culture media at 2×106 cells/mL. Monoclonal antibodies or TriNKETs targeting the tumor antigen were diluted in culture media. Activated NK cells were harvested, washed, and resuspended at 2×106 cells/mL in culture media. Cancer cells were then mixed with monoclonal antibodies/TriNKETs and activated NK cells in the presence of IL-2. Brefeldin-A and monensin were also added to the mixed culture to block protein transport out of the cell for intracellular cytokine staining. Fluorophore-conjugated anti-CD107a was added to the mixed culture and the culture was incubated for 4 hrs before samples were prepared for FACS analysis using fluorophore-conjugated antibodies against CD3, CD56 and IFN-gamma. CD107a and IFN-gamma staining was analyzed in CD3−CD56+ cells to assess NK cell activation. The increase in CD107a/IFN-gamma double-positive cells is indicative of better NK cell activation through engagement of two activating receptors rather than one receptor.
TriNKETs mediate activation of human NK cells co-cultured with HER2-expressing NCI-H661 cells (
TriNKETs mediate activation of human NK cells co-cultured with CD33-expressing human AML Mv4-11 cells as shown by an increase of CD107a degranulation and IFN-gamma production (
Peripheral blood mononuclear cells (PBMCs) were isolated from human peripheral blood buffy coats using density gradient centrifugation. NK cells (CD3−CD56+) were isolated using negative selection with magnetic beads from PBMCs, and the purity of the isolated NK cells was typically >90%. Isolated NK cells were cultured in media containing 100 ng/mL IL-2 for activation or rested overnight without cytokine. IL-2-activated or rested NK cells were used the following day in cytotoxicity assays.
In order to test the ability of human NK cells to lyse cancer cells in the presence of TriNKETs, a cytoTox 96 non-radioactive cytotoxicity assay from Promega (G1780) was used according to manufacturer's instruction. Briefly, human cancer cells expressing a tumor antigen were harvested, washed, and resuspended in culture media at 1−2×105 cells/mL. Rested and/or activated NK cells were harvested, washed, and resuspended at 105−2.0×106 cells/mL in the same culture media as that of the cancer cells. In each well of a 96 well plate, 50 μl of the cancer cell suspension was mixed with 50 μl of NK cell suspension with or without TriNKETs targeting the tumor antigen expressed on the cancer cells. After incubation at 37° C. with 5% CO2 for 3 hours and 15 minutes, 10× lysis buffer was added to wells containing only cancer cells, and to wells containing only media for the maximum lysis and negative reagent control respectively. The plate was then placed back into the incubator for an additional 45 minutes to reach a total of 4 hours incubation. Cells were then pelleted, and the culture supernatant was transferred to a new 96 well plate and mixed with a substrate for development. The new plate was incubated for 30 minutes at room temperature, and the absorbance was read at 492 nm on a SpectraMax i3x. Percentage of specific lysis of the cancer cells was calculated as follows: % Specific lysis=((experimental lysis−spontaneous lysis from NK cells alone−spontaneous lysis from cancer cells alone)/(Maximum lysis−negative reagent control))*100%
TriNKETs mediate cytotoxicity of human NK cells against the CD33-positive Molm-13 human AML cell line. As shown in
TriNKETs mediate cytotoxicity of human NK cells against the HER2-positive 786-O human renal cell carcinoma cell line. As shown in
As described above, ADI-27749 (A49) contains, inter alia, a heavy chain CDR3 having the amino acid sequence of GAPMGAAAGWFDP (SEQ ID NO:71). The Met at position 102 of SEQ ID NO:7 (i.e., at position 4 of this CDR3 sequence) may be replaced by Gln, Leu, Ile, Phe, or Val, thereby generating NKG2D antibodies A49MQ, A49ML, A49MI, A49MF, and A49MV, respectively, having the corresponding heavy chain variable region, light chain variable region, and CDR sequences provided in Table 1.
The effects of these mutations on hydrophobicity were analyzed using the MOE2018.01 program using the parameter setting of avg_pro_patch_cdr_hyd. Residues were mutated using the protein builder module and entire Fab was minimized after tethering all residues. Dynamic property sampling was performed using the lowMD protocol in BIOMOE. As shown in Table 11, these mutations did not have a substantial negative effect on the predicted hydrophobicity of the A49 Fab.
The hydrophobicity of a TriNKET containing A49 (“TriNKET A”) and a mutant form of TriNKET A having a substitution of Ile, Leu, Val, Gln, or Phe for the Met (“TriNKET A*”) were tested by analytical hydrophobic interaction chromatography (HIC). Each of the TriNKETs also bound to a first tumor antigen. As shown in Table 12, the retention time of TriNKET A* was similar to that of TriNKET A.
Thermal stability of TriNKET A and TriNKET A* was examined by differential scanning calorimetry analysis (DSC) in 20 mM Histidine, 260 mM sucrose, and 0.005% PS-80 at pH 6.0. The values of the Tm are shown in Table 13, where Tm is the midpoint transition temperature of an individual domain. The M102 mutation had a small effect on the Tm values of the two most stable transitions (Tm3 and Tm4) by shifting them 0.6 and 0.7° C. lower, compared to the TriNKET A. The earlier transitions (Tm1 and Tm2) were unaffected. Therefore, the M102 mutation had only a marginal effect on the overall thermal stability of TriNKET A.
Binding of TriNKET A and TriNKET A* to a fusion protein of human NKG2D and murine Fc (“mFc-hNKG2D”) was characterized by surface plasmon resonance (SPR) at 37° C. Two different fits, steady state affinity fit and kinetic fit, were utilized to obtain the equilibrium affinity data (
As shown in Table 14, the equilibrium affinity constants (KD) obtained from both the affinity and kinetic fits were very similar between the replicates, which suggested a high confidence in the measured parameters. The M102 variant has less than 2-fold reduced affinity for human NKG2D compared to TriNKET A. The KD for TriNKET A* was (6.87±0.16)×10−7 M, while the KD for TriNKET A was (4.87±0.83)×10−7 M (calculated from the affinity fit). Similar differences in affinities were observed when KD was calculated from the kinetic fit. The stoichiometry of NKG2D binding to TriNKET A* was 0.85±0.12, similar to the 1.01±0.11 for TriNKET A, confirming that each NKG2D dimer binds to one molecule of TriNKET A*. This suggests that the M102 mutation had only a minor effect on the binding of an A49-containing TriNKET to human NKG2D.
Finally, the effect of the M102 mutation on the potency of TriNKETs was assessed in a cytotoxicity assay. Briefly, KHYG-1 cells expressing the high-affinity variant of CD16a (158V) were generated through retroviral transduction. Following transduction, cells were selected in puromycin-containing growth media to generate a selected population of KHYG-1-CD16V cells. The selected population was maintained in media containing 10 ng/mL human IL-2. To prepare the KHYG-1-CD16V cells for use as effectors in cytotoxicity assays, the cells were harvested from culture, pelleted, washed three times in culture media without IL-2, and resuspended in culture media without IL-2 and rested for 24 hours.
Human cancer cell lines expressing a target of interest were harvested from culture. The cells were washed with HBS, and were resuspended in growth media at 106 cells/mL for labeling with BATDA reagent (Perkin Elmer C136-100). Manufacturer instructions were followed for labeling of the target cells. After labeling, the cells were washed three times with HBS and were resuspended at 0.5×105 cells/mL in culture media. 100 μl of BATDA labeled cells were added to each well of a 96-well plate.
TriNKETs were serially diluted in culture media, and 50 μl of a diluted TriNKET was added to each well. Rested NK cells were harvested from culture, washed, and resuspended at 1.0×106 cells/mL in culture media. 50 μl of NK cells were added to each well of the plate to attain a desired E:T ratio of 10:1 and to make a total of 200 μl culture volume in each well. The plate was incubated at 37° C. with 5% CO2 for 2-3 hours.
After the culturing, the plate was removed from the incubator, and the cells were pelleted by centrifugation at 200×g for 5 minutes. 20 μl of culture supernatant was transferred to a clean microplate provided from the manufacturer. Supernatant from the labeled cells incubated alone without NK cells was used to measure spontaneous release of TDA. Supernatant from labeled cells incubated with 1% Triton-X was used to measure maximum lysis of the target cells. Supernatant from the labeled cells prior to the 2-3 hours of incubation was used to measure the background and for quality control purposes.
200 μl of room temperature europium solution (Perkin Elmer C135-100) was added to each well containing culture supernatant. The plate was protected from light and incubated on a plate shaker at 250 rpm for 15 minutes. Fluorescence was measured using a SpectraMax i3X instrument. The fluorescent levels represented lysis of the target cells. The values of % specific lysis were calculated as: % specific lysis=((Experimental release−Spontaneous release)/(Maximum release−Spontaneous release))×100%.
To measure the activity of TriNKET A and TriNKET A*, a cell line that expressed the first tumor antigen was selected as target cells. Two different lots of TriNKET A were used for comparison. The % specific lysis values were plotted in
To confirm that the absence of effect of the M102 mutation on TriNKET activity was not tumor antigen-specific, TriNKET A and TriNKET A* that bind to a second, different tumor antigen were constructed. The activity of the two TriNKETs were compared in cytotoxicity assays using a cell line that expressed the second tumor antigen as target cells and KHYG-1-CD16V cells as effector cells. As shown in
The entire disclosure of each of the patent documents and scientific articles referred to herein is included by reference for all purposes.
The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The foregoing embodiments are therefore to be considered in all respects illustrative rather than limiting the invention described herein. Scope of the invention is thus indicated by the appended claims rather than by the foregoing description, and all changes that come within the meaning and range of equivalency of the claims are intended to be embraced therein.
This application is a divisional of U.S. patent application Ser. No. 16/967,216, filed on Aug. 4, 2020, which is a U.S. national stage application, filed under 35 U.S.C. § 371, of International Application No. PCT/US2019/017330, filed on Feb. 8, 2019, which claims the benefit of and priority to U.S. Provisional Patent Application No. 62/628,161, filed on Feb. 8, 2018, and U.S. Provisional Patent Application No. 62/716,259, filed on Aug. 8, 2018. The disclosure of each of the applications above, except for U.S. Provisional Patent Application No. 62/716,259, is incorporated by reference herein in its entirety for all purposes.
| Number | Name | Date | Kind |
|---|---|---|---|
| 5776427 | Thorpe et al. | Jul 1998 | A |
| 5807706 | Carter et al. | Sep 1998 | A |
| 5863538 | Thorpe et al. | Jan 1999 | A |
| 5959084 | Ring et al. | Sep 1999 | A |
| 6036955 | Thorpe et al. | Mar 2000 | A |
| 6054297 | Carter et al. | Apr 2000 | A |
| 6129914 | Weiner et al. | Oct 2000 | A |
| 6165464 | Hudziak et al. | Dec 2000 | A |
| 6210670 | Berg | Apr 2001 | B1 |
| 6294167 | Lindhofer et al. | Sep 2001 | B1 |
| 6387371 | Hudziak et al. | May 2002 | B1 |
| 6399063 | Hudziak et al. | Jun 2002 | B1 |
| 6407213 | Carter et al. | Jun 2002 | B1 |
| 6572856 | Taylor et al. | Jun 2003 | B1 |
| 6737056 | Presta | May 2004 | B1 |
| 7112324 | Dorken et al. | Sep 2006 | B1 |
| 7235641 | Kufer et al. | Jun 2007 | B2 |
| 7575923 | Dorken et al. | Aug 2009 | B2 |
| 7635472 | Kufer et al. | Dec 2009 | B2 |
| 7642228 | Carter et al. | Jan 2010 | B2 |
| 7695936 | Carter et al. | Apr 2010 | B2 |
| 7820166 | Lanzavecchia | Oct 2010 | B2 |
| 7879985 | Urso et al. | Feb 2011 | B2 |
| 7951917 | Arathoon et al. | May 2011 | B1 |
| 8007796 | Baeuerle et al. | Aug 2011 | B2 |
| 8076459 | Hofmeister et al. | Dec 2011 | B2 |
| 8101722 | Kufer et al. | Jan 2012 | B2 |
| 8236308 | Kischel et al. | Aug 2012 | B2 |
| 8409577 | Thompson et al. | Apr 2013 | B2 |
| 8518403 | Hoffmann et al. | Aug 2013 | B2 |
| 8591897 | Bryant | Nov 2013 | B2 |
| 8658765 | Martin, Jr. et al. | Feb 2014 | B2 |
| 8759494 | Bachmann et al. | Jun 2014 | B2 |
| 8784821 | Kufer et al. | Jul 2014 | B1 |
| 8796420 | Martin, Jr. et al. | Aug 2014 | B2 |
| 8840888 | Nagorsen et al. | Sep 2014 | B2 |
| 9079969 | Martin, Jr. et al. | Jul 2015 | B2 |
| 9102736 | Hofmeister et al. | Aug 2015 | B2 |
| 9127064 | Urso et al. | Sep 2015 | B2 |
| 9150656 | Johnson et al. | Oct 2015 | B2 |
| 9150663 | Labrijn et al. | Oct 2015 | B2 |
| 9200078 | Bachmann | Dec 2015 | B2 |
| 9248181 | De Kruif et al. | Feb 2016 | B2 |
| 9248182 | De Kruif et al. | Feb 2016 | B2 |
| 9273136 | Rader et al. | Mar 2016 | B2 |
| 9334331 | Igawa et al. | May 2016 | B2 |
| 9493578 | Lazar et al. | Nov 2016 | B2 |
| 9562109 | Von Kreudenstein et al. | Feb 2017 | B2 |
| 9587036 | Kufer et al. | Mar 2017 | B2 |
| 9637557 | Scheer et al. | May 2017 | B2 |
| 9683053 | Blein et al. | Jun 2017 | B2 |
| 9690969 | Okamoto | Jun 2017 | B2 |
| 9718893 | Jung et al. | Aug 2017 | B2 |
| 9951145 | Kim et al. | Apr 2018 | B2 |
| 9963513 | Vu et al. | May 2018 | B2 |
| 10040853 | Spies et al. | Aug 2018 | B2 |
| 10047167 | Demarest et al. | Aug 2018 | B2 |
| 10059765 | Velardi et al. | Aug 2018 | B2 |
| 10377827 | Swanson et al. | Aug 2019 | B2 |
| 10421807 | Gonzales et al. | Sep 2019 | B2 |
| 10526409 | Urso et al. | Jan 2020 | B2 |
| 11124582 | Ambrogelly et al. | Sep 2021 | B2 |
| 11834506 | Chang et al. | Dec 2023 | B2 |
| 20020103345 | Zhu | Aug 2002 | A1 |
| 20020193569 | Hanna | Dec 2002 | A1 |
| 20040038339 | Kufer et al. | Feb 2004 | A1 |
| 20040052783 | Weiner et al. | Mar 2004 | A1 |
| 20040115198 | Spies et al. | Jun 2004 | A1 |
| 20050037002 | Velardi et al. | Feb 2005 | A1 |
| 20050054019 | Michaud et al. | Mar 2005 | A1 |
| 20050058639 | Gudas et al. | Mar 2005 | A1 |
| 20050158307 | Spies et al. | Jul 2005 | A1 |
| 20050244416 | Jung | Nov 2005 | A1 |
| 20060018899 | Kao et al. | Jan 2006 | A1 |
| 20060235201 | Kischel | Oct 2006 | A1 |
| 20060246004 | Adams et al. | Nov 2006 | A1 |
| 20070004909 | Johnson et al. | Jan 2007 | A1 |
| 20070071759 | Shin et al. | Mar 2007 | A1 |
| 20070179086 | Gliniak et al. | Aug 2007 | A1 |
| 20070190063 | Bahjat et al. | Aug 2007 | A1 |
| 20080025975 | Weiner et al. | Jan 2008 | A1 |
| 20080299137 | Svendsen et al. | Dec 2008 | A1 |
| 20080305105 | Kufer et al. | Dec 2008 | A1 |
| 20090142352 | Jackson et al. | Jun 2009 | A1 |
| 20090175867 | Thompson et al. | Jul 2009 | A1 |
| 20090226442 | Huet et al. | Sep 2009 | A1 |
| 20090226466 | Fong et al. | Sep 2009 | A1 |
| 20090252729 | Farrington et al. | Oct 2009 | A1 |
| 20090304693 | Ghayur et al. | Dec 2009 | A1 |
| 20090304696 | Lawson et al. | Dec 2009 | A1 |
| 20100009866 | Prinz et al. | Jan 2010 | A1 |
| 20100055034 | Martin et al. | Mar 2010 | A1 |
| 20100056764 | Urso et al. | Mar 2010 | A1 |
| 20100124764 | Hufton et al. | May 2010 | A1 |
| 20100174053 | Johnson et al. | Jul 2010 | A1 |
| 20100178298 | Lindhofer | Jul 2010 | A1 |
| 20100260765 | Barry et al. | Oct 2010 | A1 |
| 20100272718 | Urso et al. | Oct 2010 | A1 |
| 20100286374 | Kannan et al. | Nov 2010 | A1 |
| 20100291112 | Kellner et al. | Nov 2010 | A1 |
| 20100310463 | Cicortas Gunnarsson et al. | Dec 2010 | A1 |
| 20110008335 | Velardi et al. | Jan 2011 | A1 |
| 20110020273 | Chang et al. | Jan 2011 | A1 |
| 20110044980 | Ghayur et al. | Feb 2011 | A1 |
| 20110054151 | Lazar et al. | Mar 2011 | A1 |
| 20110150870 | Rader et al. | Jun 2011 | A1 |
| 20110311535 | Dranoff et al. | Dec 2011 | A1 |
| 20120014957 | Ghayur et al. | Jan 2012 | A1 |
| 20120058082 | Kaplan et al. | Mar 2012 | A1 |
| 20120058906 | Smider et al. | Mar 2012 | A1 |
| 20120093823 | Van Den Brink et al. | Apr 2012 | A1 |
| 20120149876 | Von Kreudenstein et al. | Jun 2012 | A1 |
| 20120171173 | Ideno et al. | Jul 2012 | A1 |
| 20120195900 | Ghayur et al. | Aug 2012 | A1 |
| 20120263722 | Ghayur et al. | Oct 2012 | A1 |
| 20120269723 | Brinkmann et al. | Oct 2012 | A1 |
| 20120294796 | Johnson et al. | Nov 2012 | A1 |
| 20120294857 | Sentman et al. | Nov 2012 | A1 |
| 20120321626 | Zhou | Dec 2012 | A1 |
| 20120328619 | Fey et al. | Dec 2012 | A1 |
| 20130115208 | Ho et al. | May 2013 | A1 |
| 20130177555 | Wilkinson et al. | Jul 2013 | A1 |
| 20130209514 | Gilboa et al. | Aug 2013 | A1 |
| 20130216528 | Cheung et al. | Aug 2013 | A1 |
| 20130216544 | Bachmann | Aug 2013 | A1 |
| 20130230525 | Li et al. | Sep 2013 | A1 |
| 20130336977 | Thompson et al. | Dec 2013 | A1 |
| 20140044739 | Teng et al. | Feb 2014 | A1 |
| 20140072579 | De Kruif et al. | Mar 2014 | A1 |
| 20140072581 | Dixit et al. | Mar 2014 | A1 |
| 20140105889 | Igawa et al. | Apr 2014 | A1 |
| 20140112926 | Liu et al. | Apr 2014 | A1 |
| 20140120096 | Bakker et al. | May 2014 | A1 |
| 20140127203 | Thompson et al. | May 2014 | A1 |
| 20140140999 | De Kruif et al. | May 2014 | A1 |
| 20140141022 | Thompson et al. | May 2014 | A1 |
| 20140154250 | Thompson et al. | Jun 2014 | A1 |
| 20140154252 | Thompson et al. | Jun 2014 | A1 |
| 20140199294 | Mimoto et al. | Jul 2014 | A1 |
| 20140234342 | Narni-Mancinelli et al. | Aug 2014 | A1 |
| 20140242077 | Choi et al. | Aug 2014 | A1 |
| 20140271617 | Igawa et al. | Sep 2014 | A1 |
| 20140288275 | Moore et al. | Sep 2014 | A1 |
| 20140294827 | Gastwirt et al. | Oct 2014 | A1 |
| 20140302064 | Moore | Oct 2014 | A1 |
| 20140363426 | Moore et al. | Dec 2014 | A1 |
| 20140364340 | Vasquez et al. | Dec 2014 | A1 |
| 20150050269 | Igawa et al. | Feb 2015 | A1 |
| 20150056206 | Zhou | Feb 2015 | A1 |
| 20150079088 | Lowman et al. | Mar 2015 | A1 |
| 20150119555 | Jung et al. | Apr 2015 | A1 |
| 20150166636 | Igawa et al. | Jun 2015 | A1 |
| 20150166654 | Igawa et al. | Jun 2015 | A1 |
| 20150175697 | Bonvini et al. | Jun 2015 | A1 |
| 20150175700 | Lum et al. | Jun 2015 | A1 |
| 20150203591 | Yancopoulos et al. | Jul 2015 | A1 |
| 20150210765 | Roschke et al. | Jul 2015 | A1 |
| 20150259431 | Stemmer et al. | Sep 2015 | A1 |
| 20150259434 | Johnson et al. | Sep 2015 | A1 |
| 20150274838 | Johnson et al. | Oct 2015 | A1 |
| 20150299319 | Velardi et al. | Oct 2015 | A1 |
| 20150307617 | Du et al. | Oct 2015 | A1 |
| 20150307628 | Kim et al. | Oct 2015 | A1 |
| 20150329637 | Urech et al. | Nov 2015 | A1 |
| 20150353636 | Parren et al. | Dec 2015 | A1 |
| 20160017038 | Koenig | Jan 2016 | A1 |
| 20160024214 | Urso et al. | Jan 2016 | A1 |
| 20160032009 | Cheung et al. | Feb 2016 | A1 |
| 20160039942 | Cobbold et al. | Feb 2016 | A1 |
| 20160046727 | Labrijn et al. | Feb 2016 | A1 |
| 20160046730 | Ghayur et al. | Feb 2016 | A1 |
| 20160077105 | Bobrowicz et al. | Mar 2016 | A1 |
| 20160090426 | Zhou et al. | Mar 2016 | A1 |
| 20160096892 | Brogdon et al. | Apr 2016 | A1 |
| 20160122432 | Baty et al. | May 2016 | A1 |
| 20160159882 | Landgraf et al. | Jun 2016 | A1 |
| 20160159924 | Padkjaer et al. | Jun 2016 | A1 |
| 20160176968 | Chang et al. | Jun 2016 | A1 |
| 20160289341 | Wu | Oct 2016 | A1 |
| 20160326249 | Ng et al. | Nov 2016 | A1 |
| 20160347849 | Cai et al. | Dec 2016 | A1 |
| 20160369002 | Gauthier et al. | Dec 2016 | A1 |
| 20170022291 | Baruah et al. | Jan 2017 | A1 |
| 20170029529 | Croasdale et al. | Feb 2017 | A1 |
| 20170066827 | Pule et al. | Mar 2017 | A1 |
| 20170114141 | Amann et al. | Apr 2017 | A1 |
| 20170233472 | Barat et al. | Aug 2017 | A1 |
| 20170291955 | Li et al. | Oct 2017 | A1 |
| 20170362321 | Campbell et al. | Dec 2017 | A1 |
| 20170368169 | Loew et al. | Dec 2017 | A1 |
| 20170369595 | Brinkmann et al. | Dec 2017 | A1 |
| 20180044415 | Escarpe et al. | Feb 2018 | A1 |
| 20180057608 | Jung et al. | Mar 2018 | A1 |
| 20180105594 | Urso et al. | Apr 2018 | A1 |
| 20180105599 | Cobbold et al. | Apr 2018 | A1 |
| 20180118851 | Comeau et al. | May 2018 | A1 |
| 20180237519 | Caligiuri et al. | Aug 2018 | A1 |
| 20180273633 | Jiang et al. | Sep 2018 | A1 |
| 20180312592 | Junutula et al. | Nov 2018 | A1 |
| 20190048079 | Spies et al. | Feb 2019 | A1 |
| 20190225702 | Baeuerle et al. | Jul 2019 | A1 |
| 20190359716 | Chang et al. | Nov 2019 | A1 |
| 20190375838 | Chang et al. | Dec 2019 | A1 |
| 20200002436 | Chang et al. | Jan 2020 | A1 |
| 20200024353 | Chang et al. | Jan 2020 | A1 |
| 20200048347 | Miao et al. | Feb 2020 | A1 |
| 20200055939 | Lombana et al. | Feb 2020 | A1 |
| 20200095327 | Chang et al. | Mar 2020 | A1 |
| 20200157174 | Chang et al. | May 2020 | A1 |
| 20200157226 | Chang et al. | May 2020 | A1 |
| 20200157227 | Chang et al. | May 2020 | A1 |
| 20200165344 | Chang et al. | May 2020 | A1 |
| 20200216544 | Chang et al. | Jul 2020 | A1 |
| 20200231678 | Chang et al. | Jul 2020 | A1 |
| 20200231679 | Chang et al. | Jul 2020 | A1 |
| 20200231700 | Cheung et al. | Jul 2020 | A1 |
| 20200277383 | Chang et al. | Sep 2020 | A1 |
| 20200277384 | Chang et al. | Sep 2020 | A1 |
| 20200376034 | Chang et al. | Dec 2020 | A1 |
| 20210009718 | Ambrogelly et al. | Jan 2021 | A1 |
| 20210032349 | Dengl et al. | Feb 2021 | A1 |
| 20210054082 | Chang et al. | Feb 2021 | A1 |
| 20210070887 | Ambrogelly et al. | Mar 2021 | A1 |
| 20210079102 | Chang et al. | Mar 2021 | A1 |
| 20210101976 | Chang et al. | Apr 2021 | A1 |
| 20210130471 | Chang et al. | May 2021 | A1 |
| 20210130474 | Chang et al. | May 2021 | A1 |
| 20210130496 | Chang et al. | May 2021 | A1 |
| 20210198369 | Chang et al. | Jul 2021 | A1 |
| 20210206859 | Chang et al. | Jul 2021 | A1 |
| 20210214436 | Chang et al. | Jul 2021 | A1 |
| 20210221894 | Bigelow et al. | Jul 2021 | A1 |
| 20210238290 | Chang et al. | Aug 2021 | A1 |
| 20210261668 | Chang et al. | Aug 2021 | A1 |
| 20210292420 | Chang et al. | Sep 2021 | A1 |
| 20210363261 | Chang et al. | Nov 2021 | A1 |
| 20220025037 | Baruah et al. | Jan 2022 | A1 |
| 20220119534 | Baruah et al. | Apr 2022 | A1 |
| 20220195065 | Chang et al. | Jun 2022 | A1 |
| 20220380459 | Chang et al. | Dec 2022 | A1 |
| Number | Date | Country |
|---|---|---|
| 2990511 | Dec 2016 | CA |
| 102378768 | Mar 2012 | CN |
| 105906722 | Aug 2016 | CN |
| 102013019352 | Sep 2015 | DE |
| 627940 | Dec 1994 | EP |
| 845998 | Jun 1998 | EP |
| 871673 | Oct 1998 | EP |
| 1124568 | Aug 2001 | EP |
| 1769000 | Apr 2007 | EP |
| 2185595 | May 2010 | EP |
| 2222706 | Sep 2010 | EP |
| 2927321 | Oct 2015 | EP |
| 2930188 | Oct 2015 | EP |
| 2942629 | Nov 2015 | EP |
| 2982380 | Feb 2016 | EP |
| 2990416 | Mar 2016 | EP |
| 2588668 | Jul 2016 | RU |
| 2593720 | Aug 2016 | RU |
| WO-1988008854 | Nov 1988 | WO |
| WO-1989006544 | Jul 1989 | WO |
| WO-1996027011 | Sep 1996 | WO |
| WO-2001071005 | Sep 2001 | WO |
| WO-2004056873 | Jul 2004 | WO |
| WO-2006037960 | Apr 2006 | WO |
| WO-2007002905 | Jan 2007 | WO |
| WO-2007042573 | Apr 2007 | WO |
| WO-2007055926 | May 2007 | WO |
| WO-2007097812 | Aug 2007 | WO |
| WO-2009007124 | Jan 2009 | WO |
| WO-2009077483 | Jun 2009 | WO |
| WO-2009089004 | Jul 2009 | WO |
| WO-2010017103 | Feb 2010 | WO |
| WO-2010080124 | Jul 2010 | WO |
| WO-2011014659 | Feb 2011 | WO |
| WO-2011075636 | Jun 2011 | WO |
| WO-2011109400 | Sep 2011 | WO |
| WO-2011131746 | Oct 2011 | WO |
| WO-2011143545 | Nov 2011 | WO |
| WO-2012006490 | Jan 2012 | WO |
| WO-2012025530 | Mar 2012 | WO |
| WO-2012032080 | Mar 2012 | WO |
| WO-2012034039 | Mar 2012 | WO |
| WO-2012045752 | Apr 2012 | WO |
| WO-2012058768 | May 2012 | WO |
| WO-2012115241 | Aug 2012 | WO |
| WO-2012125850 | Sep 2012 | WO |
| WO-2012158818 | Nov 2012 | WO |
| WO-2012162482 | Nov 2012 | WO |
| WO-2013013700 | Jan 2013 | WO |
| WO-2013036799 | Mar 2013 | WO |
| WO-2013092001 | Jun 2013 | WO |
| WO-2013192594 | Dec 2013 | WO |
| WO-2014001324 | Jan 2014 | WO |
| WO-2014012085 | Jan 2014 | WO |
| WO-2014079000 | May 2014 | WO |
| WO-2014084607 | Jun 2014 | WO |
| WO-2014110601 | Jul 2014 | WO |
| WO-2014124326 | Aug 2014 | WO |
| WO-2014131712 | Sep 2014 | WO |
| WO-2014144763 | Sep 2014 | WO |
| WO-2014145806 | Sep 2014 | WO |
| WO-2014159940 | Oct 2014 | WO |
| WO-2014165818 | Oct 2014 | WO |
| WO-2014198748 | Dec 2014 | WO |
| WO-2015009856 | Jan 2015 | WO |
| WO-2015036582 | Mar 2015 | WO |
| WO-2015036606 | Mar 2015 | WO |
| WO-2015063187 | May 2015 | WO |
| WO-2015070061 | May 2015 | WO |
| WO-2015077891 | Jun 2015 | WO |
| WO-2015089344 | Jun 2015 | WO |
| WO-2015095412 | Jun 2015 | WO |
| WO-2015095539 | Jun 2015 | WO |
| WO-2015095972 | Jul 2015 | WO |
| WO-2015150447 | Oct 2015 | WO |
| WO-2015153765 | Oct 2015 | WO |
| WO-2015153912 | Oct 2015 | WO |
| WO-2015158636 | Oct 2015 | WO |
| WO-2015169781 | Nov 2015 | WO |
| WO-2015181282 | Dec 2015 | WO |
| WO-2015184203 | Dec 2015 | WO |
| WO-2015184207 | Dec 2015 | WO |
| WO-2015197582 | Dec 2015 | WO |
| WO-2015197593 | Dec 2015 | WO |
| WO-2015197598 | Dec 2015 | WO |
| WO-2016001810 | Jan 2016 | WO |
| WO-2016011571 | Jan 2016 | WO |
| WO-2016023909 | Feb 2016 | WO |
| WO-2016025880 | Feb 2016 | WO |
| WO-2016028672 | Feb 2016 | WO |
| WO-2016032334 | Mar 2016 | WO |
| WO-2016070959 | May 2016 | WO |
| WO-2016090278 | Jun 2016 | WO |
| WO-2016097408 | Jun 2016 | WO |
| WO-2016100533 | Jun 2016 | WO |
| WO-2016109774 | Jul 2016 | WO |
| WO-2016115274 | Jul 2016 | WO |
| WO-2016122701 | Aug 2016 | WO |
| WO-2016134371 | Aug 2016 | WO |
| WO-2016135041 | Sep 2016 | WO |
| WO-2016135066 | Sep 2016 | WO |
| WO-2016142768 | Sep 2016 | WO |
| WO-2016146702 | Sep 2016 | WO |
| WO-2016161390 | Oct 2016 | WO |
| WO-2016164369 | Oct 2016 | WO |
| WO-2016164637 | Oct 2016 | WO |
| WO-2016166139 | Oct 2016 | WO |
| WO-2016184592 | Nov 2016 | WO |
| WO-2016187220 | Nov 2016 | WO |
| WO-2016191305 | Dec 2016 | WO |
| WO-2016196237 | Dec 2016 | WO |
| WO-2016201300 | Dec 2016 | WO |
| WO-2016201389 | Dec 2016 | WO |
| WO-2016207273 | Dec 2016 | WO |
| WO-2016207278 | Dec 2016 | WO |
| WO-2017005732 | Jan 2017 | WO |
| WO-2017008169 | Jan 2017 | WO |
| WO-2017011342 | Jan 2017 | WO |
| WO-2017021349 | Feb 2017 | WO |
| WO-2017048824 | Mar 2017 | WO |
| WO-2017075432 | May 2017 | WO |
| WO-2017079694 | May 2017 | WO |
| WO-2017081190 | May 2017 | WO |
| WO-2017083545 | May 2017 | WO |
| WO-2017114694 | Jul 2017 | WO |
| WO-2017124002 | Jul 2017 | WO |
| WO-2017125897 | Jul 2017 | WO |
| WO-2017143406 | Aug 2017 | WO |
| WO-2017165464 | Sep 2017 | WO |
| WO-2017165683 | Sep 2017 | WO |
| WO-2017177337 | Oct 2017 | WO |
| WO-2017180813 | Oct 2017 | WO |
| WO-2017211873 | Dec 2017 | WO |
| WO-2017218707 | Dec 2017 | WO |
| WO-2018045090 | Mar 2018 | WO |
| WO-2018098365 | May 2018 | WO |
| WO-2018119171 | Jun 2018 | WO |
| WO-2018148445 | Aug 2018 | WO |
| WO-2018148447 | Aug 2018 | WO |
| WO-2018148566 | Aug 2018 | WO |
| WO-2018148610 | Aug 2018 | WO |
| WO-2018152516 | Aug 2018 | WO |
| WO-2018152518 | Aug 2018 | WO |
| WO-2018152530 | Aug 2018 | WO |
| WO-2018152547 | Aug 2018 | WO |
| WO-2018157147 | Aug 2018 | WO |
| WO-2018201051 | Nov 2018 | WO |
| WO-2018217799 | Nov 2018 | WO |
| WO-2018217945 | Nov 2018 | WO |
| WO-2018217947 | Nov 2018 | WO |
| WO-2019028027 | Feb 2019 | WO |
| WO-2019035939 | Feb 2019 | WO |
| WO-2019040727 | Feb 2019 | WO |
| WO-2019051308 | Mar 2019 | WO |
| WO-2019055677 | Mar 2019 | WO |
| WO-2019157332 | Aug 2019 | WO |
| WO-2019157366 | Aug 2019 | WO |
| WO-2019164929 | Aug 2019 | WO |
| WO-2019164930 | Aug 2019 | WO |
| WO-2019195408 | Oct 2019 | WO |
| WO-2019195409 | Oct 2019 | WO |
| WO-2019217332 | Nov 2019 | WO |
| WO-2019222449 | Nov 2019 | WO |
| WO-2019231920 | Dec 2019 | WO |
| WO-2020033587 | Feb 2020 | WO |
| WO-2020033630 | Feb 2020 | WO |
| WO-2020033664 | Feb 2020 | WO |
| WO-2020033702 | Feb 2020 | WO |
| WO-2020086758 | Apr 2020 | WO |
| WO-2020172189 | Aug 2020 | WO |
| WO-2021041878 | Mar 2021 | WO |
| WO-2021076564 | Apr 2021 | WO |
| WO-2021216916 | Oct 2021 | WO |
| WO-2021226193 | Nov 2021 | WO |
| WO-2022031965 | Feb 2022 | WO |
| WO-2022187539 | Sep 2022 | WO |
| WO-2023056252 | Apr 2023 | WO |
| WO-2023107956 | Jun 2023 | WO |
| WO-2023154796 | Aug 2023 | WO |
| WO-2023168384 | Sep 2023 | WO |
| Entry |
|---|
| U.S. Appl. No. 16/483,330, filed Aug. 2, 2019. |
| U.S. Appl. No. 16/483,788, filed Aug. 6, 2019. |
| U.S. Appl. No. 16/486,569, filed Aug. 16, 2019. |
| U.S. Appl. No. 17/190,155, filed Mar. 2, 2021. |
| U.S. Appl. No. 16/967,216, filed Aug. 4, 2020. |
| U.S. Appl. No. 17/053,558, filed Nov. 6, 2020. |
| Affimed, Affimed Enters Into Collaboration With Merck to Evaluate AFM13 in Combination With . . . Retreived < U RL:https ://www.affimed.com/affi med-enters-into-collaboration-with-merck-to-evaluate-afm 13-i n-combination-with-keytruda-pembrolizumab-for-patients-with-hodgkin-lymphoma/>[retrieved on Feb. 1, 2023] Jan. 25, 2016. |
| Ahmad et al. (2012) “scFv antibody: principles and clinical application,” Clinical and Developmental Immunology 2012:1-16. |
| Akbar et al. (2021) “A compact vocabulary of paratope-epitope interactions enables predictability of antibody-antigen binding,” Cell Reports 34:108856 (21 pages). |
| Altshuler et al. (2010) “Generation of Recombinant Antibodies and Means for Increasing Their Affinity,” Biochemistry (Moscow) 75(13):1584-1605. |
| Atwell et al. (1989) “Stable Heterodimers from Remodeling the Domain Interface of a Homodimer using a Phage Display Library,” J Mol Biol 270:26-35. |
| Averdam et al. (2009) “A Novel System of Polymorphic and Diverse NK Cell Receptors in Primates,” PLoS Genetics 5(10):e1000688. |
| Baek et al. (2014) “Construction of a Large Synthetic Human Fab Antibody Library on Yeast Cell Surface by Optimized Yeast Mating,” J Microbial Biotechnol 24(3):408-420. |
| Bartlett et al. (2007) “Lenalidomide and pomalidomide strongly enhance tumor cell killing in vitro during antibody-dependent cellular cytotoxicity (ADCC) mediated by trastuzumab, cetuximab and rituximab,” American Society of Clinical Oncology, 25(18S) (19 pages). |
| Bendayan et al. (1995) “Possibilities of False Immunocytochemical Results Generated by the Use of Monoclonal Antibodies: The Example of the Anti-proinsulin Antibody,” J. Histochem. Cytochem. 43:881-886. |
| Berenbaum (1977) “Synergy, additivism and antagonism in immunosuppression,” Clin. Exp. Immunol. 28:1-18. |
| Berenbaum (1989) “What is Synergy?” Pharmacological Reviews 41:93-141. |
| Bogen et al. (2021) “Design of a Trispecific Checkpoint Inhibitor and Natural Killer Cell Engager Based on a 2+1 Common Light Chain Antibody Architecture,” Frontiers in Immunology 12:16 pages. |
| Boltz (2011) “Bi-specific Aptamers mediating Tumour Cell Lysis,” Dissertation, M.Sc. Molekulare Biotechnologie, Technische Universität Darmstadt, pp. 1-133. |
| Bost et al. (1988) “Antibodies Against a Peptide Sequence Within the HIV Envelope Protein Crossreacts with Human Interleukin-2,” Immunological Investigations 17(6&7):577-586. |
| Bostrom, et al. (2009) “Improving Antibody Binding Affinity and Specificity for Therapeutic Development,” Methods and Protocols 525:353-376. |
| Bowen et al. (2016) “Revisiting the Immunoglobulin Intramolecular Signaling Hypothesis,” Trends Immunol. 37(11):721-723. |
| Branca et al. (2018) “Nature Biotechnology's academic spinouts of 2017,” Nature Biotechnology 36(4):297-306. |
| Briney et al. (2019) “Commonality despite exceptional diversity in the baseline human antibody repertoire,” Nature 566:393 (19 pages). |
| Brinkmann et al. (2017) “The making of bispecific antibodies,” MABS 9(2):182-212. |
| Brown et al. (1996) “Tolerance of single, but not multiple, amino acid replacements in antibody VH CDR 2: a means of minimizing B cell wastage from somatic hypermutation?,” Journal of Immunology, 156: 3285-3291. |
| Bruhns et al. (2009) “Specificity and affinity of human FCγ receptors and their polymorphic variants for human IgG subclasses,” Blood 113(16):3716-3724. |
| Bryceson et al. (2006) “Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion,” Blood 107(1):159-166. |
| Busfield et al. (2014) “Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC,” Leukemia 28(11): 2213-2221. |
| Cai et al. (2014) “Autonomous Stimulation of Cancer Cell Plasticity by the Human NKG2D Lymphocyte Receptor Coexpressed with Its Ligands on Cancer Cells,” PLOS One 9(10):e108942. |
| Casset et al. (2003) “A peptide mimetic of an anti-CD4 monoclonal antibody by rational design,” Biochemical and Biophysical Research Communications 307:198-205. |
| Chan et al. (2010) “Therapeutic antibodies for autoimmunity and inflammation,” Nature Reviews 10:301-316. |
| Chen et al. (1995) “Enhancement and destruction of antibody function by somatic mutation: unequal occurrence is controlled by V gene combinatorial associations,” The EMBO Journal 14(12):2784-2794. |
| Chen et al. (1999) “Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-matured Fab in Complex with Antigen,” J. Mol. Biol. 293:865-881. |
| Chen X. et al. (2013) “Fusion protein linkers: property, design and functionality” Advanced drug delivery reviews, 65(10):1357-1369. |
| Cho et al. (2010) “Delivery of NKG2D Ligand Using an Anti-HER2 Antibody-NKG2D Ligand Fusion Protein Results in an Enhanced Innate and Adaptive Antitumor Response,” Cancer Research 70(24):10121-10130. |
| Choi et al. (2013) “A Heterodimeric Fc-Based Bispecific Antibody Simultaneously Targeting VEGFR-2 and Met Exhibits Potent Antitumor Activity,” Mol Cancer Ther. 12(12):2748-2759. |
| Choi et al. (2015) “Crystal structures of immunoglobulin Fc heterodimers reveal the molecular basis for heterodimer formation,” Molecular Immunology 65(2):377-83. |
| Choi et al. (2015) “Engineering of Immunoglobulin Fc Heterodimers Using Yeast Surface-Displayed Combinatorial Fc Library Screening,” PloS One. Dec. 16, 2015; 10(12);e0145349; pp. 1-20. |
| Chu, S. et al. (2014) “Immunotherapy with Long-Lived Anti-CD123 x Anti-CD3 Bispecific Antibodies Stimulates Potent T Cell-Mediated Killing of Human AML Cell Lines and of CD123+ Cells in Monkeys: A Potential Therapy for Acute Myelogenous Leukemia 11,” Blood 124(21):2316. |
| Colman P. M. (1994) “Effects of amino acid sequence changes on antibody-antigen interactions” Research in Immunology 145(1):33-36. |
| Cunningham et al. (1969) “Subgroups of Amino Acid Sequences in the Variable Regions of Immunoglobulin Heavy Chains,” Proc Natl Acad Sci USA 64(3):997-1003. |
| Dahlberg et al. (2015) “Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and sustain Anti-Tumor Activity” Frontiers in Immunology 6(Article 605):19 pages. |
| Dasgupta et al. (2005) “Inhibition of NK Cell Activity through TGF-β1 by Down-Regulation of NKG2D in a Murine Model of Head and Neck Cancer,” J Immunol 175(8):5541-5550. |
| Davis et al. (2010) “SEEDbodies: Fusion Proteins Based on Strand-Exchange Engineered Domain (SEED) CH3 Heterodimers in an Fc Analogue Platform for Asymmetric Binders or Immunofusions and Bispecific Antibodies,” Protein Eng Des Sel 23(4):195-202. |
| De Pascalis et al. (2002) “Grafting of “Abbreviated” Complementarity-Determining Regions Containing Specificity-Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibody,” The Journal of Immunology 169:3076-3084. |
| Demaria et al. (2021) “Natural killer cell engagers in cancer immunotherapy: Next generation of immuno-oncology treatments,” Eur. J. Immunol. 51:1934-1942. |
| Dickopf et al. (2020) “Format and geometries matter: Structure-based design defines the functionality of bispecific antibodies,” Computational and Structural Biotechnology Journal 18:1221-1227. |
| Ding et al. (2018) “Fusion Proteins of NKG2D/NKG2DL in Cancer Immunotherapy,” International Journal of Molecular Sciences 19(1):177. |
| Edwards et al. (2003) “The Remarkable Flexibility of the Human Antibody Repertoire; Isolation of Over One Thousand Different Antibodies to a Single Protein, BLyS,” J. Mol. Biol. 334:103-118. |
| El-Amine et al. (2002) “In vivo induction of tolerance by an Ig peptide is not affected by the deletion of FcR or a mutated IgG Fc fragment,” International Immunology 14(7):761-766. |
| Elliott et al. (2014) “Antiparallel conformation of knob and hole aglycosylated half-antibody homodimers is mediated by a CH2—CH3 hydrophobic interaction”, J. Mol. Biol., 426(9):1947-57. |
| Felices et al. (2016) “Generation of BiKEs and TriKEs to Improve NK cell-Mediated Targeting of Tumor Cells,” Natural Killer Cells: Methods and Protocols, Methods in Molecular Biology 1441:333-346. |
| Feng et al. (2011) “Design, Expression and Characterization of a Soluble Single-Chain Functional Human Neonatal Fc Receptor,” Protein Expr Purif 79(1):66-71. |
| Feng et al., (2020) “NKG2D-Fc fusion protein promotes antitumor immunity through the depletion of immunosuppressive cells,” Cancer Immunol. Immunother. 69(10):2147-2155. |
| Gantke et al. (2016) “Trispecific Antibodies for Selective CD16A-Directed NK-Cell Engagement in Multiple Myeloma,” Blood 128(22):4513. |
| Gantke et al. (2017) “Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells,” Protein Engineering, Design & Selection 38(9):673-684. |
| Gauthier et al. (2019) “Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity,” Cell 177(7):1701-1713. |
| Germain et al. (2005) “MHC Class I-Related Chain a Conjugated to Antitumor antibodies Can Sensitize Tumor Cells to Specific Lysis by Natural Killer Cells,” Clinical Cancer Research US 11(20):7516-7522. |
| Germain et al. (2008) “Redirecting NK cells mediated tumor cell lysis by a new recombinant bifunctional protein,” Protein Engineering, Design & Selection 21(11):665-672. |
| Giuliani et al. (2017) “Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression,” Oncotarget 8(14):24031-24044. |
| Glas et al. (1997) “Analysis of rearranged immunoglobulin heavy chain variable region genes obtained from a bone marrow transplant (BMT) recipient,” Clinical & Experimental Immunology 107(2):372-380. |
| Gleason et al. (2012) “Bispecific and Trispecific Killer Cell Engagers Directly Activate Human NK Cells through CD16 Signaling and Induce Cytotoxicity and Cytokine Production,” Molecular Cancer Therapeutics 11(12):2674-2684. |
| Gleason et al. (2014) “CD16×CD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets,” Blood 123(19):3016-3026. |
| Goel et al. (2004) “Plasticity within the Antigen-Combining Site May Manifest as Molecular Mimicry in the Humoral Immune Response,” The Journal of Immunology 173(12):7358-7367. |
| Gonzales, et al. (2005) “Minimizing the Immunogenicity of Antibodies for Clinical Application,” Tumor Biol. 26(1):31-43. |
| Gooden et al. (2012) “Infiltrating CTLs are bothered by HLA-E on tumors,” Oncolmmunology, 1(1):92-93. |
| Gunasekaran et al. (2010) “Enhancing Antibody Fc Heterodimer Formation through Electrostatic Steering Effects: Applications to Bispecific Molecules and Monovalent IgG,” J Biol Chem 285(25):19637-46. |
| Ha et al. (2016) “Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins,” Front Immunol. 7:394, 16 pages. |
| Han et al. (2018) “Control of triple-negative breast cancer using ex vivo self-enriched, constimulated NKG2D CAR T cells,” 11:92 13 pages. |
| Hasegawa et al. (2017) “Single amino acid substitution in LC-CDR1 induces Russell body phenotype that attenuates cellular protein synthesis through eIF2α phosphorylation and thereby downregulates IgG secretion despite operational secretory pathway traffic,” MABS 9(5):854-873. |
| Henry et al. (2004) “A Prostate-Specific Membrane Antigen-Targeted Monoclonal Antibody-Chemotherapeutic Conjugate Designed for the Treatment of Prostate Cancer,” Cancer Research 64:7995-8001. |
| Henry et al. (2017) “Stability-Diversity Tradeoffs Impose Fundamental Constraints on Selection of Synthetic Human VH/VL Single-Domain Antibodies from In Vitro Display Libraries,” Frontiers in Immunology, 8:1-15. |
| Herold et al. (2017) “Determinants of the assembly and function of antibody variable domains,” Scientific Reports, 7:12276. |
| Hezareh et al. (2001) “Effector Function Activities of a Panel of Mutants of a Broadly Neutralizing Antibody against Human Immunodeficiency Virus Type 1,” Journal of Virology 75(24):12161-12168. |
| Hilpert et al. (2012) “Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses,” J Immunol. 189(3):1360-71. |
| Hlavacek et al. 1999 “Steric Effects on Multivalent Ligand-Receptor Binding: Exclusion of Ligand Sites by Bound Cell Surface Receptors,” Biophysical Journal 76:3031-3043. |
| Holliger et al. (2005) “Engineered antibody fragments and the rise of single domains,” Nat Biotechnol 23(9): 1126-36. |
| Hoseini et al. (2017) “Acute myeloid leukemia targets for bispecific antibodies,” Blood Cancer Journal 7(2):e522 (12 pages). |
| Jachimowicz et al. (2011) “Induction of In Vitro and In Vivo NK Cell Cytotoxicity Using High-Avidity Immunoligands Targeting Prostate-Specific Membrane Antigen in Prostate Carcinoma,” Mol Cancer Thera, 10(6):1036-1045. |
| Janeway et al. (1997) Chapter 3, Structure of the Antibody Molecule and Immunoglobulin Genes, Immunology Third Edition, Garland Publishing Inc., 3:1-3:11. |
| Jonnalagadda et al. (2015) “Chimeric Antigen Receptors With Mutated IgG4 Fc Spacer Avoid Fc Receptor Binding and Improve T Cell Persistence and Antitumor Efficacy,” Molecular Therapy 23(4):757-768. |
| Jorge Flavio Mendoza Rincón (2014) “El receptor NKG2D en la frontera de la inmunovigilancia y la carcinogénesis,” Publicación Científica en Ciencias Biomédicas 2(21):237-43. |
| Junttila et al. (2014) “Antitumor Efficacy of a Bispecific Antibody That Targets HER2 and Activates T Cells,” Cancer Research 74(19):5561-5571. |
| Kanyavuz et al. (2019) “Breaking the law: unconventional strategies for antibody diversification,” Nature Reviews Immunology 19(6):355-368. |
| Katano et al. (2015) “Predominant Development of Mature and Functional Human NK Cells in a Novel Human IL-2-Producing Transgenic NOG Mouse” J. Immunol. 194(7):3513-3525. |
| Kaur et al. (2015) “Applications of In Vitro-In Vivo Correlations in Generic Drug Development: Case Studies,” The AAPS Journal 17(4):1035-1039; doi: 10.1208/s12248-015-9765-1. |
| Kellner et al. (2012) “Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicity,” Leukemia 26:830-834. |
| Kellner et al. (2013) “Promoting natural killer cell functions by recombinant immunoligands mimicking an induced self phenotype,” Oncoimmunology 2(6):e24481. |
| Kellner et al. (2016) “Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30,” Oncolmmunology 5(1):e1058459-1-e1058459-12. |
| Khan et al. (2014) “Adjustable Locks and Flexible Keys: Plasticity of Epitope-Paratope Interactions in Germline Antibodies,” J. Immunol 192:5398-5405. |
| Kijanka et al. (2013) “Rapid optical imaging of human breast tumour xenografts using anti-HER2 VHHs site-directly conjugated to IRDye 800CW for image-guided surgery,” Eur J Nucl Med Mol Imaging 40:1718-1729. |
| Kim et al. (2014) “Mutational approaches to improve the biophysical properties of human single-domain antibodies,” Biochimica et Biophysica Acta, 1844:1983-2001. |
| Kjellev et al. (2007) “Inhibition of NKG2D receptor function by antibody therapy attenuates transfer-induced colitis in SCID mice,” Eur. J. Immunol. 37:1397-1406. |
| Klein et al. (2012) “Progress in overcoming the chain association issue in bispecific; heterodimeric IgG antibodies,” mAbs 4(6):653-663. |
| Kluge et al. (2017) “EGFR/CD16A TandAbs are efficacious NK-cell engagers with favorable biological properties which potently kill EGFR(+) tumors with and without Ras mutation,” Cancer Research 77(13 Suppl.):Abstract 3641. |
| Koerner et al. (2015) “Induction of NK and T Cell Immune Responses Against Leukemia Cells by Bispecific NKG2D-CD16 and -CD3 Fusion Proteins,” Blood 126(23):2558, Abstract 606 (2 pages). |
| Kranz et al. (1981) “Restricted reassociation of heavy and light chains from hapten-specific monoclonal antibodies,” Pro. Natl. Acad. Sci. USA 78(9):5807-5811. |
| Krieg et al. (2005) “Functional Analysis of B and T Lymphocyte Attenuator Engagement on CD4+ and CD8+ T Cells,” The Journal of Immunology 175(10):6420-6427. |
| Kunik, et al. (2012) “Structural consensus among antibodies defines the antigen binding site,” PLoS Comput Biol. 8(2):e1002388. |
| Kwong et al. (2008) “Generation, affinity maturation, and characterization of a human anti-human NKG2D monoclonal antibody with dual antagonistic and agonistic activity,” Journal of Molecular Biology 384(5):1143-1156. |
| Lamminmäki et al. (2001) “Crystal Structure of a Recombinant Anti-estradiol Fab Fragment in Complex with 17β-Estradiol,” The Journal of Biological Chemistry 276(39):36687-36694. |
| Lewis et al. (2014) “Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface,” Nat Biotechnol 32(2):191-98. |
| Lin et al. (2011) “Improved affinity of a chicken single-chain antibody to avian infectious bronchitis virus by site-directed mutagenesis of complementarity-determining region H3,” African Journal of Biotechnology 10(79):18294-18303. |
| Lin et al. (2013) “CD4+ NKG2D+ T cells induce NKG2D down-regulation in natural killer cells in CD86-RAE-1 E transgenic mice,” Immunology 141(3):401-415. |
| Lippow et al. (2007) “Computational design of antibody-affinity improvement beyond in vivo maturation,” Nature Biotechnology 25(10):1171-1176. |
| Liu et al. (2017) “Fc engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds,” Frontiers in Immunology 8(38):1-15. |
| Lloyd et al. (2009) “Modelling the human immune response: performance of a 1011 human antibody repertoire against a broad panel of therapeutically relevant antigens,” Protein Engineering, Design and Selection 22(3):159-168. |
| Lo et al. (2021) “Conformational epitope matching and prediction based on protein surface spiral features,” BMC Genomics 22(Suppl 2):116 16 pages. |
| Long et al. (2013) “Controlling NK Cell Responses: Integration of Signals for Activation and Inhibition,” Annu Rev Immunol. 2013 ; 31: 10.1146/annurev-immunol-020711-075005. |
| Lund et al. (1996) “Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc gamma receptor I and influence the synthesis of its oligosaccharide chains,” J. Immunol 157:4963-4969. |
| MacCallum et al. (1996) “Antibody-antigen Interactions: Contact Analysis and Binding Site Topography,” J. Mol. Biol. 262:732-745. |
| Madlener et al. (2010) “A Bispecific Protein Targeting the NKG2D Receptor on Natural Killer Cells: In Vitro and In Vivo activity of ULBP2-CEA,” Blood 116(21):2095. |
| Maeda et al. (2015) “New antibody modification technology and its application to antibody drugs,” Farumashia 51(5):424-428. |
| Maeda Y. et al. (1997) “Engineering of Functional Chimeric Protein G-Vargula Luciferase” Analytical biochemistry, 249(2):147-152. |
| Maelig et al. (2016) “NK cells and cancer: you can teach innate cells new tricks”, Nature Reviews Cancer, 16(1):7-19. |
| Mandelboim et al. (1999) “Human CD16 as a lysis receptor mediating direct natural killer cell cytotoxicity,” PNAS USA 96(10):5640-5644; doi: 10.1073/pnas.96.10.5640. |
| Mariuzza et al. (1987) “The Structural Basis of Antigen-Antibody Recognition,” Ann. Rev. Biophys. Chem. 16:139:59. |
| Marks et al. (2020) “How repertoire data are changing antibody science,” J. Biol. Chem. 295(29):9823-9837. |
| McCarthy et al. (2001) “Altering the fine specificity of an anti-Legionella single chain antibody by a single amino acid insertion,” Journal of Immunological Methods 251:137-149. |
| McWilliams, et al. (2016) “Targeting the Tumor Evasion Interaction of NKG2A and Its Ligand HLA-E Increases Natural-Killer Cell Activity in Chronic Lymphocytic Leukemia,” Blood 1289-1291. |
| Merchant et al. (1998), “An efficient route to human bispecific IgG,” Nature Biotechnology 16, 677-681 doi : 10.1038/nbt0798-677. |
| Miller et al. (2003) “Design, Construction, and in Vitro Analyses of Multivalent Antibodies,” J Immunol 170(9):4854-61. |
| Miller et al. (2018) “Annual Review of Cancer Biology Natural Killer Cells in Cancer Immunotherapy,” Annu. Rev. Cancer Biol. 8(3):77-103. |
| Miller et al. 2019 “Natural Killer Cells in Cancer Immunotherapy,” Ann. Rev. Cancer Biol. 3:77-103. |
| Mimoto et al. (2014) “Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcyRs,” Mo/ Immunol 58(1):132-38. |
| Moore et al. (2011) “A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens,” mAbs 3:6, 546-557; Nov./Dec. 2011, Landes Bioscience, DOI: 10.4161/mabs.3.6.18123. |
| Morris “Epitope Mapping of Protein Antigens by Competition ELISA,” The Protein Protocols Handbook, Totowa, NJ, Humana Press, (19960101):595-600. |
| Morvan et al. (2016).“NK cells and cancer: you can teach innate cells new tricks” Nat Rev Cancer 16(1):7-19. |
| Muda et al. (2011) “Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies,” Protein Eng Des Se/ 24(5):447-54. |
| Muller et al. (2015) “Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade,” Sci. Transl. Med. 7(315):1-14. |
| Muntasell et al. (2017) “Interplay between Natural Killer Cells and Anti-HER2 Antibodies:Perspectives for Breast Cancer Immunotherapy,” Front. Immunol. 8:1544, doi: 10.3389/fimmu.2017.01544, 15 pages. |
| Muntasell et al. (2017) “Targeting NK-cell checkpoints for cancer immunotherapy,” Current Opinion in Immunology 45:73-81. |
| Myers et al. (2021) “Exploring the NK cell platform for cancer immunotherapy,” Nature Reviews Clinical Oncology 18(2):85-100. |
| Nagasaki et al. (2014) “Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour-stroma interaction,” British Journal of Cancer 110(2):469-478. |
| Nie et al. (2020) “Biology drives the discovery of bispecific antibodies as innovative therapeutics,” Antibody Therapeutics 3(1):18-62. |
| Notice of Opposition for Colombia Patent Application No. NC2020/0010345 dated Dec. 16, 2020. |
| Padlan et al. (1989) “Structure of an antibody-antigen complex: Crystal structure of the HyHEL-10 Fab-lysozyme complex,” Pro. Natl. Acad. Sci. USA 86:5938-5942. |
| Pakula et al. (1989) “Genetic Analysis of Protein Stability and Function,” Annu. Rev. Genet. 23:289-310. |
| Parsons et al. (2016) “NKG2D Acts as a Co-Receptor for Natural Killer Cell-Mediated Anti-HIV-1 Antibody-Dependent Cellular Cytotoxicity,” AIDS Research and Human Retroviruses 32(10-11) 1089-1096. |
| Paul et al. (1993) “Fundamental Immunology,” (textbook) 292-295. |
| Petricevic et al. (2013) “Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients,” Journal of Translational Medicine 11(307). |
| Piche-Nicholas et al. (2018) “Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics,” MABS 10(1)81-94. |
| Poosaria et al. (2017) “Computational de novo Design of Antibodies binding to a Peptide with High Affinity,” 114(6):1331-1342. |
| Portolano et al. (1993) “Lack of promiscuity in autoantigen-specific H and L chain combinations as revealed by human H and L chain roulette,” J. Immunol. 15(30):880-887. |
| Powers et al. (2016) “Abstract 1407: FPA 144, a therapeutic monoclonal antibody targeting the FGFR2b receptor, promotes antibody dependent cell-mediated cytotoxicity and stimulates sensitivity to PD-1 in the 4T1 syngeneic tumor model,” Cancer Research (4 pages). |
| Raab et al. (2014) “Fc-Optimized NKG2D-Fc Constructs Induce NK Cell Antibody-Dependent Cellular Cytotoxicity Against Breast Cancer Cells Independently of HER2/neu Expession Status,” Journal of Immunology 193(8):4261-72. |
| Rabia et al. (2018) “Understanding and overcoming trade-offs between antibody affinity, specificity, stability and solubility” Biochem Eng J. 137:365-374. |
| Raulet (2003) “Roles of the NKG2D immunoreceptor and its ligands,” Nature: Reviews Immunology 3:781-790; doi: 10.1038/nri1199. |
| Ridgway et al. (1996) “‘Knobs-into-Holes’ engineering of antibody Ch3 domains for heavy chain heterodimerization,” Protein Engineering 9(7):617-21. |
| Roda-Navarro et al. (2020) “Understanding the Spatial Topology of Artificial Immunological Synapses Assembled in T Cell-Redirecting Strategies: A Major Issue in Cancer Immunotherapy,” Frontiers in Cell and Developmental Biology 7:1-5. |
| Roell et al. (2017) “An Introduction to Terminology and Methoodology of Chemical Synergy—Perspectives from Across Disciplines,” Frontiers in Pharmacology: Cancer Molecular Targets and Therapeutics 8:1-11. |
| Romee et al. (2013) “NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17),” Blood 121(18):3599-608. |
| Rosano et al. (2014) “Recombinant protein expression in Escherichia coli: advances and challenges” Frontiers in Microbiology 5(172):17 pages. |
| Rothe et al. (2013) “The Bispecific Immunoligand ULBP2-aCEA Redirects Natural Killer Cells to Tumor Cells and Reveals Potent Anti-Tumor Activity Against Colon Carcinoma,” Int. J. Cancer 134(12):2829-2840. |
| Rudikoff et al. (1982) “Single amino acid substitution altering antigen-binding specificity,” Pro. Natl. Acad. Sci USA 79:1979-1983. |
| Safdari Y. et al. (2013) “Antibody humanization methods—a review and update” Biotechnology and Genetic Engineering Reviews, 29(2):175-186. |
| Sazinsky et al. (2008) “Aglycosylated immunoglobulin G1 variants productively engage activating receptors,” Proceedings of the National Academy of Sciences 105(51)20167-20172. |
| Schroeder et al. (2010) “Structure and Function of Immunoglobulins,” J Allergy Clin Immunol 125:S41-S52 (24 pages). |
| Schuster et al. (2015) “Immunotherapy with the trifunctional anti-CD20 x anti-CD3 antibody FBTA05 (Lymphomun) in paediatric high-risk patients with recurrent CD20-positive B cell malignancies,” British Journal of Haematology 169(1):90-102. |
| Shen J. et al. (2006) “Single variable domain-IgG fusion: a novel recombinant approach to Fc domain-containing bispecific antibodies” Journal of Biological Chemistry, 281(16):10706-10714. |
| Shum et al. (2002) “Conservation and Variation in Human and Common Chimpanzee CD94 and NKG2 Genes,” The Journal of Immunology 168:240-252. |
| Siena et al. (2010) “Reduced Incidence of Infusion-Related Reactions in Metastatic Colorectal Cancer During Treatment With Cetuximab Plus Irinotecan With Combined Corticosteroid and Antihistamine Premedication,” Cancer 116(7):1827-1837. |
| Singer et al. (1998) “Genes and Genomes,” Moscow, “Mir” 1:63-64. |
| Smits et al. (2016) “Designing multivalent proteins based on natural killer cell receptors and their ligands as immunotherapy for cancer,” Expert Opinion on Biological Therapy 16(9):1105-1112. |
| Sondermann et al. (2000) “The 3.2-Å crystal structure of the human IgG1 Fc fragment-Fc[gamma]RIII complex,” Nature 406(6793):267-273. |
| Spear et al. (2013) “NKG2D ligands as therapeutic targets,” Cancer Immunology 13:8. |
| Spiess et al. (2015) “Alternative molecular formats and therapeutic applications for bispecific antibodies,” Molecular Immunology 67:95-106. |
| Stamova et al. (2011) “Simultaneous engagement of the activatory receptors NKG2D and CD3 for retargeting of effector cells to CD33-positive malignant cells,” Leukemia 25:1053-1056. |
| Steigerwald et al. (2009) “Human IgG1 antibodies antagonizing activating receptor NKG2D on natural killer cells,” mAbs 1(2):115-127. |
| Stein et al. (2012) “Natural Killer (NK)- and T-Cell Engaging Antibody-Derived Therapeutics,” Antibodies 1:88-123. |
| Steinbacher et al. (2015) “An Fc-optimized NKG2D-immunoglobulin G fusion protein for induction of natural killer cell reactivity against leukemia,” International Journal of Cancer 136(5):1073-1084. |
| Strong (2002) “Asymmetric ligand recognition by the activating natural killer cell receptor NKG2D, a symmetric homodimer,” Molecular Immunology 38(14):1029-1037. |
| Strop et al. (2012) “Generating Bispecific Human IgG1 and IgG2 Antibodies from Any Antibody Pair,” J Mol Biol 420:204-19. |
| Sulea et al. (2018) “Application of Assisted Design of Antibody and Protein Therapeutics (ADAPT) improves efficacy of a Clostridium difficile toxin A single-domain antibody,” 8:2260 11 pages. |
| Tallarida (2000) “Drug Synergism and Dose Effect Analysis,” Ed. Chapman & Hall pp. 1-71. |
| Tay et al. (2016) “TriKEs and BiKEs join CARs on the cancer immunotherapy highway,” Human Vaccines & Immunotherapeutics 12(11):2790-2796. |
| Teplyakov A. et al. (2014) “Antibody modeling assessment II. Structures and models” Proteins: Structure, Function, and Bioinformatics, 82(8):1563-1582. |
| Thakur et al. (2018) “Bispecific antibody based therapeutics: Strengths and challenges,” Blood Review 32:339-347. |
| Torres M. et al. (2008) “The immunoglobulin constant region contributes to affinity and specificity” Trends in immunology, 29(2):91-97. |
| Trivedi et al. (2017) “Clinical pharmacology and translational aspects of bispecific antibodies,” Clin. Transl. Sci., 10:147-162. |
| Vajda et al. (2021) “Progress toward improved understanding of antibody maturation,” Current Opinion in Structural Biology 67:226-231. |
| Vajdos et al. (2002) “Comprehensive Functional Maps of the Antigen-binding Site of an Anti-ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis,” J. Mol. Biol. 320:415-428. |
| Vaks et al. (2018) “Design Principles for Bispecific IgGs, Opportunities and Pitfalls of Artificial Disulfide Bonds,” Antibodies 7(27):1-28. |
| Vallera et al. (2016) “IL 15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function,” Clin Cancer Res, 22(14):3440-50. |
| Van de Winkel et al. (1993) “Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications,” Immunology Today 14(5):215-221. |
| Vidarsson et al. (2014) “IgG subclasses and allotypes: from structure to effector functions,” Front. Immunol. 5:520, 17 pages. |
| Von Kreudenstein et al. (2013) “Improving Biophysical Properties of a Bispecific Antibody Scaffold to Aid Developability: Quality by Molecular Design,” mAbs 5(5):646-54. |
| Von Kreudenstein et al. (2014), “Protein Engineering and the Use of Molecular Modeling and Simulation: The Case of Heterodimeric Fc Engineering,” Methods 65(1):77-94. |
| Von Strandmann et al. (2006) “A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo,” Blood 107(5):1955-1962. |
| Vyas et al. (2016) “Mono- and dual-targeting triplebodies activate natural killer cells and have anti-tumor activity in vitro and in vivo against chronic lymphocytic leukemia,” Oncoimmunology 5(9):p. e1211220. |
| Wang et al. (2016) “A bispecific protein rG7S-MICA recruits natural killer cells and enhances NKG2D-mediated immunosurveillance against hepatocellular carcinoma,” Cancer Letters 372(2):166-178. |
| Wang et al. (2018) “IgG Fc engineering to modulate antibody effector functions,” Protein Cell 9(1):63-73. |
| Ward et al. (1989) “Binding activities of a epertoire of single immunoglobulin variable domains secreted from Escherichia coli,” Nature 341:544-546. |
| Wark et al. (2006) “Latest technologies for the enhancement of antibody affinity”, Advanced Drug Delivery Reviews 58(5-6):657-670. |
| Watanabe et al. (2014) NKG2D functions as an activating receptor on natural killer cells in the common marmoset (Callithrix jacchus) International Immunology 26(11):597-606. |
| Weiss-Steider et al. (2011) “Expression of MICA, MICB and NKG2D in human leukemic myelomonocytic and cervical cancer cells,” Journal of Experimental & Clinical Cancer Research 30(1):37. |
| Wensveen et al. (2018) “NKG2D: A Master Regulator of Immune Cell Responsiveness,” Frontiers in Immunology 9(Article 411):8 pages. |
| Whalen et al. (2023) “Engaging natural killer cells for cancer therapy via NKG2D, CD16A and other receptors,” 15(1) 15 pages. |
| Wikipedia: “Trifunctional antibody Feb. 1, 2018”,, Jan. 2, 2018 (Jan. 2, 2018), pp. 1-4, XP093016568, Retrieved from the Internet: URL:https://en.wikipedia.org/w/index.php?title=Trifunctional antibody8 oldid=818265015. |
| Wranik et al. (2012) “LUZ-Y, a novel platform for the mammalian cell production of full-length IgG-bispecific antibodies,” J Biol Chem 287(52):43331-9. |
| Written Opinion for International Application No. PCT/US2019/017330 dated Jun. 11, 2019. |
| Wu et al. (1999) “Humanization of a Murine Monoclonal Antibody by Simultaneous Optimization of Framework and CDR Residues,” J. Mol. Biol. 294:151-162. |
| Wu et al. (2011), “Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers,” Cancer Immunology, Immunotherapy, Springer, 60(1):61-73. |
| Xie et al. (2005) “A new format of bispecific antibody: highly efficient heterodimerization, expression and tumor cell lysis,” J Immunol Methods 296(1):95-101. |
| Xie et al. (2015) “VEGFR2 targeted antibody fused with MICA stimultes NKG2D mediated immunosurveillance and exhibits potent anti-tumor activity against breast cancer,” Oncotarget 7(13):16455-16471. |
| Xu et al. (2014) “Production of bispecific antibodies in “knobs-into-holes” using a cell-free expression system,” mAbs 7(1)231-242. |
| Xu et al. (2019) “A VEGFR2-MICA bispecific antibody activates tumor-infiltrating lymphocytes and exhibits potent anti-tumor efficacy in mice,” Cancer Immunology Immunotherapy 68(9):1429-1441. |
| Yan et al. (2014) “Construction of a synthetic phage-displayed Nanobody library with CDR3 regions randomized by trinucleotide cassettes for diagnostic applications,” Journal of Translational Medicine 12:343 (12 pages). |
| Yang et al. (2017) “Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies” Int. J. Mol. Sci. 18(48) 21 pages. |
| Yeap et al. (2016) “CD16 is indispensable for antibody dependent cellular cytotoxicity by human monocytes,” Scientific Reports 6:34310. |
| Young et al. (1995) “Thermal stabilization of a single-chain Fv antibody fragment by introduction of a disulphide bond,” FEBS Letters 377(2):135-139. |
| Zhang et al. (2021) “Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity,” Journal for ImmunoTherapy of Cancer; 9:e002980 (24 pages). doi:10.1136/jitc-2021-002980. |
| Zhou et al. (1995) “Characterization of human homologue of 4-1BB and its ligand,” Immunology Letters 45:67-73. |
| U.S. Appl. No. 16/483,330, filed Aug. 2, 2019, U.S. Pat. No. 11,834,506, Dec. 5, 2023. |
| U.S. Appl. No. 18/482,629, filed Oct. 6, 2023. |
| U.S. Appl. No. 16/484,936, filed Aug. 9, 2019. |
| U.S. Appl. No. 16/486,921, filed Aug. 19, 2019. |
| U.S. Appl. No. 16/486,569, filed Aug. 16, 2019, U.S. Pat. No. 11,884,732, Jan. 30, 2024. |
| U.S. Appl. No. 18/541,475, filed Dec. 15, 2023. |
| U.S. Appl. No. 18/304,652, filed Apr. 21, 2023. |
| U.S. Appl. No. 17/095,238, filed Nov. 11, 2020. |
| U.S. Appl. No. 18/107,292, filed Feb. 8, 2023. |
| U.S. Appl. No. 16/615,231, filed Nov. 20, 2019. |
| U.S. Appl. No. 16/615,261, filed Nov. 20, 2019. |
| U.S. Appl. No. 16/635,079, filed Jan. 29, 2020. |
| U.S. Appl. No. 17/188,978, filed Mar. 1, 2021. |
| U.S. Appl. No. 16/639,150, filed Feb. 14, 2020. |
| U.S. Appl. No. 18/108,961, filed Feb. 13, 2023. |
| U.S. Appl. No. 16/645,613, filed Mar. 9, 2020. |
| U.S. Appl. No. 16/967,216, filed Aug. 4, 2020, U.S. Pat. No. 11,884,733, Jan. 30, 2024. |
| U.S. Appl. No. 18/501,413, filed Nov. 3, 2023. |
| U.S. Appl. No. 18/501,427, filed Nov. 3, 2023. |
| U.S. Appl. No. 17/058,335, filed Nov. 24, 2020. |
| U.S. Appl. No. 16/971,098, filed Aug. 19, 2020. |
| U.S. Appl. No. 16/967,218, filed Aug. 4, 2020. |
| U.S. Appl. No. 18/149,965, filed Jan. 4, 2023. |
| U.S. Appl. No. 18/150,040, filed Jan. 4, 2023. |
| U.S. Appl. No. 17/045,015, filed Oct. 2, 2020. |
| U.S. Appl. No. 17/055,792, filed Nov. 16, 2020. |
| U.S. Appl. No. 17/265,876, filed Feb. 4, 2021. |
| U.S. Appl. No. 17/543,628, filed Dec. 6, 2021. |
| U.S. Appl. No. 17/266,349, filed Feb. 5, 2021. |
| U.S. Appl. No. 17/265,879, filed Feb. 4, 2021. |
| U.S. Appl. No. 17/266,966, filed Feb. 8, 2021. |
| U.S. Appl. No. 17/929,282, filed Sep. 1, 2022. |
| U.S. Appl. No. 17/287,849, filed Apr. 22, 2021. |
| U.S. Appl. No. 16/971,104, filed Aug. 19, 2020. |
| U.S. Appl. No. 17/682,367, filed Feb. 28, 2022. |
| U.S. Appl. No. 17/769,160, filed Apr. 14, 2022. |
| U.S. Appl. No. 18/003,308, filed Dec. 23, 2022. |
| U.S. Appl. No. 17/920,174, filed Oct. 20, 2022. |
| U.S. Appl. No. 17/308,691, filed May 5, 2021. |
| U.S. Appl. No. 17/686,238, filed Mar. 3, 2022. |
| U.S. Appl. No. 18/062,453, filed Dec. 6, 2022. |
| U.S. Appl. No. 18/166,769, filed Feb. 9, 2023. |
| U.S. Appl. No. 18/177,847, filed Mar. 3, 2023. |
| U.S. Appl. No. 18/366,876, filed Aug. 8, 2023. |
| Kim et al. (1995) “Evidence That the Hinge Region Plays a Role in Maintaining Serum Levels of the Murine IgG1 Molecule,” Molecular Immunology 32(7):467-475. |
| Watzl et al. (2010) “Signal Transduction During Activation and Inhibition of Natural Killer Cells”, Curr Protoc Immunol., 90(1):11.9B1-11.9B.17. |
| Yang et al. (2017) “Enhancing NK cell-mediated cytotoxicity to cisplatin-resistant lung cancer cells via MEK/Erk signaling inhibition,” Nature Scientific Reports, 7:7958 (13 pages). |
| Number | Date | Country | |
|---|---|---|---|
| 20240067735 A1 | Feb 2024 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62716259 | Aug 2018 | US | |
| 62628161 | Feb 2018 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 16967216 | US | |
| Child | 18501419 | US |
